Testhyperlink123: Difference between revisions

Revision as of 18:29, 10 April 2023

GSD000031

term (main_entry) : Blood group A1 (Type 3) 

glycan_dictionary_accession : GSD000031 

glytoucan_accession  : G44060QH 

term_in_sentence : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:2579390] 

publication : 2579390|19756298 

definition : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] 

term_xref : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040  

synonyms : Blood group A1 (type 3)|Blood Group A1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000032

term (main_entry) : Blood group A2 (A-associated H type 3) 

glycan_dictionary_accession : GSD000032 

glytoucan_accession  : G62735WZ 

term_in_sentence : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: 3944091]
publication : 3944091|29000000|28658771 

definition : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] 

term_xref : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041|GTC:G62735WZ 

synonyms : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000033

term (main_entry) : Blood group B (Type 1) 

glycan_dictionary_accession : GSD000033 

glytoucan_accession  : G31734OS 

term_in_sentence : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633 19208633]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/18701592 18701592 18701592]|24749871|19387828|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633 19208633]|29562255 

definition : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] 

term_xref : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 

synonyms : blood group B type 1 tetrasaccharide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000034

term (main_entry) : Blood group B (Type 2) 

glycan_dictionary_accession : GSD000034 

glytoucan_accession  : G34881WK 

term_in_sentence : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062 2432062]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062 2432062]|27196314|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592 18701592] 

definition :  

term_xref : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262  

synonyms : blood group B type 2 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000035

term (main_entry) : Blood group B (Type 4) 

glycan_dictionary_accession : GSD000035 

glytoucan_accession  : G25216QA 

term_in_sentence : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:1390942] 

publication : 1390942|[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684 1841684] 

definition :  

term_xref : GlycoMotif:GGM.000087|GTC:G25216QA  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000036

term (main_entry) : Blood group H (Type 1) 

glycan_dictionary_accession : GSD000036 

glytoucan_accession  : G00294TN 

term_in_sentence : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:7718581] 

publication : 7718581|6309836|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633 19208633]|27431816|[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062 2432062]|24219248|6352465|8499478|3348768|3718924 

definition :  

term_xref : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153  

synonyms : H type 1 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:153] 

wikipedia :  

essentials_of_glycobiology :

GSD000037

term (main_entry) : Blood group H (Type 2) 

glycan_dictionary_accession : GSD000037 

glytoucan_accession  : G70519XK 

term_in_sentence : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495 9405495]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495 9405495]|8082855|6177241|3944092|21406562|2410664|8731502|6203846|2238560| 

definition :  

term_xref : GTC:G70519XK|GlycoMotif:GGM.000036  

synonyms : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II 

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000038

term (main_entry) : Blood group H (Type 2) - Lewis y 

glycan_dictionary_accession : GSD000038 

glytoucan_accession  : G00052MO 

term_in_sentence : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: 11479278] 

publication : 11479278 

definition : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] 

term_xref : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045  

synonyms : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y 

function : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] 

disease_associations : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000039

term (main_entry) : Blood group H (Type 4) 

glycan_dictionary_accession : GSD000039 

glytoucan_accession  : G98465JN 

term_in_sentence : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684 1841684]] 

publication : 11261842|[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684 1841684]|11101633|[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495 9405495] 

definition : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] 

term_xref : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245

synonyms :  

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:61] 

wikipedia :  

essentials_of_glycobiology :

GSD000040

term (main_entry) : C2-O-sLex 

glycan_dictionary_accession : GSD000040 

glytoucan_accession  : G97345NY 

term_in_sentence : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:12736247] 

publication : 12736247|19267921|21283832|15596301|17072011 

definition : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] 

term_xref : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000041

term (main_entry) : Ceramide dihexosyl sulfate 

glycan_dictionary_accession : GSD000041 

glytoucan_accession  : G04416BG 

term_in_sentence : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] 

publication : 818074 

definition : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/] 

term_xref : GTC:G04416BG|GlycoMotif:GGM.000065 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000043

term (main_entry) : Chondroitin sulfate 

glycan_dictionary_accession : GSD000043 

glytoucan_accession  :  

term_in_sentence : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: 31013685] 

publication : 31013685|[https://pubmed.ncbi.nlm.nih.gov/27526113 27526113 27526113]|27194526|26980567|28847361|24413804|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297 29891297]|29600622|25129732|31317901|29181550|[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530 31250530]|22265655|25756648|29402610|[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217 17928217]|20236040|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940 28091940]|30824935|26572336|31207331|21110089|30599999|20399897|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567 27226567]|19388612|23186102|31494830|28982096|30241863|30295666|25366475|20521042|29456007|31304829|18661362|28576008|29494632|30016441|26906924|24861964|23774590|31887904|31339761|[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856 12512856]|26957048|29625000 

definition : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] 

term_xref : CHEBI:37397|CID:24766 

synonyms : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000044

term (main_entry) : cisGM1 

glycan_dictionary_accession : GSD000044 

glytoucan_accession  : G03277YI 

term_in_sentence : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: 9455923] 

publication : 9455923 

definition : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] 

term_xref : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 

synonyms : GM1b 

function :  

disease_associations : Influenza[SugarBind_Ligand:92] 

wikipedia :  

essentials_of_glycobiology : Chapter 23

GSD000045

term (main_entry) : Complex-type N-glycans 

glycan_dictionary_accession : GSD000045 

glytoucan_accession  :  

term_in_sentence : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] 

publication : 29902282|29212795|29343819|27705835|26745022|18399796|16825488|21964725|15864431|22890903|12417032|28039392|19426135|30253927|16794314|19806620|22975979|25931033|15201278|19129634|19129628|24032650|22530754|31021709|30973186|28091941|23115339|20829342|27304954|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617 29090617]|21802690|29725121|30471292|16581187|26098720|31080188|1930135|31888963|30844485|24014058|11129583 

definition : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  

term_xref :  

synonyms :  

function : Involved in protein stability.[PMID:12417032] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 17

GSD000046

term (main_entry) : Core 2 

glycan_dictionary_accession : GSD000046 

glytoucan_accession  : G00033MO 

term_in_sentence : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: 19349303] 

publication : 19349303|30315106|23640779|26677400 

definition : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] 

term_xref : GTC:G00033MO|CID:52921656|CHEBI:62158  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000047

term (main_entry) : Core 3 

glycan_dictionary_accession : GSD000047 

glytoucan_accession  : G00035MO 

term_in_sentence : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: 28745318] 

publication : 28745318|27259834|27143302| 

definition : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] 

term_xref : GTC:G00035MO|CID:25061208|CHEBI:71344  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000048

term (main_entry) : Core 4 

glycan_dictionary_accession : GSD000048 

glytoucan_accession  : G00037MO 

term_in_sentence : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: 9988682] 

publication : 9988682|10747980| 

definition : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] 

term_xref : GTC:G00037MO| CID:25229562|CHEBI:71341 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 8

GSD000049

term (main_entry) : Core-fucosylated 

glycan_dictionary_accession : GSD000049 

glytoucan_accession  : G78059CC 

term_in_sentence : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:27678371] 

publication : 27678371|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453 24914453]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672 31268672]|28674882|29956878|27798819|32044029|30962950|31548313|30907281|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617 29090617]|29571940|28800497|27629418|29733746|31623829|28768188|26897254|31451706|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868 26514868]|29427759|28982386|26587313|30940702|[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974 15538974]|31249452|27282921|31229844|30445455|31325506|24732908|29209018|26965517|28609658|[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453 24914453]|25573275|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014 17049014]|19218400|27012207|27139574|[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267 32078267]|25861849|32561391|21374780|31669139|25732060|29408166|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672 31268672]|30472795|30614075|19003000|25664929 

definition : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006]. 

term_xref : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232 70679232]]|CHEBI:70967|CHEBI:156499 

synonyms : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc 

function : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] 

disease_associations : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis 

wikipedia :  

essentials_of_glycobiology : Chapter 8

GSD000050

term (main_entry) : Core-fucosylated biantennary 

glycan_dictionary_accession : GSD000050 

glytoucan_accession  : G78059CC 

term_in_sentence : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:9654101] 

publication : 9654101|15819890|28263871|26763099|22256781|23681398|25855029|10529240|26544759|8206921|33149259|8547276 

definition : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. 

term_xref : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232 70679232]]|CHEBI:70967|CHEBI:156499 

synonyms : core-fucosylated diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 8

GSD000051

term (main_entry) : Core-fucosylated biantennary complex-type 

glycan_dictionary_accession : GSD000051 

glytoucan_accession  : G78059CC 

term_in_sentence : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:10731668] 

publication : 10731668 

definition : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. 

term_xref : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232 70679232]]|CHEBI:70967|CHEBI:156499  

synonyms : core fucosylated diantennary complex-type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000052

term (main_entry) : Cyclic sialyl 6-sulfo Lewis x 

glycan_dictionary_accession : GSD000052 

glytoucan_accession  :  G11148DZ

term_in_sentence : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:10728707] 

publication : 10728707|31222115|9990070|23088960 

definition :  

term_xref :  GlycoEpitope:EP0017|CID:91858084|CHEBI:147484

synonyms :  

function : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000053

term (main_entry) : Cytolipin R 

glycan_dictionary_accession : GSD000053 

glytoucan_accession  : G57710SU 

term_in_sentence : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:4110375] 

publication : 893368|4375678|51702|186204|4110375|5068000|24174198|6072378|389925|7054174 

definition : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:5068000] 

term_xref : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17  

synonyms :  

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:17] 

wikipedia :  

essentials_of_glycobiology :

GSD000054

term (main_entry) : Dermatan sulfate 

glycan_dictionary_accession : GSD000054 

glytoucan_accession  :  

term_in_sentence : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:29111696] 

publication : [https://pubmed.ncbi.nlm.nih.gov/27526113 27526113 27526113]|29111696|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297 29891297]|26164146|30869126|7789716|8597249|[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856 12512856]|[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530 31250530]|[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217 17928217]|12213784|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567 27226567]|31455633|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940 28091940]|19075609|31071403|15078125|18661328|20581662|17239765|15749837|2777747|20632047|8930750|7762784|31006321|26876822|1522290|131009|26986023|8161353|15315969|12543559|30637950|2525357|18156656|9692613|9200333|19661164|2299256|16075147|1126924|9774430|8537360|15563459|21077227|23275130|17137817|6447930|6209270 

definition : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] 

term_xref : CHEBI:18376|CID:32756 

synonyms : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate 

function : Wound healing[Essentials of Glycobiology:Chapter 7]|maintain the structure of the dermis.[Essentials of Glycobiology:Chapter 41] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000055

term (main_entry) : Desialylated 

glycan_dictionary_accession : GSD000055 

glytoucan_accession  :  

term_in_sentence : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] 

publication : 30015642|26168491|29492899|31774586|32321401|23780974|7600681|18045697|1450583|4137057|28911304|27562992|29950245|31978220|2408573|8612720|10910970|27195066|1434544|22175031|24517196|29794068|30101537|18972200|1478792|4440781|21229239|30844664|31351722|31330845|1872910 

definition : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000056

term (main_entry) : Desialylated tetrasaccharide 

glycan_dictionary_accession : GSD000056 

glytoucan_accession  :  

term_in_sentence : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:8384526] 

publication : 8384526 

definition : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 17

GSD000057

term (main_entry) : Difucosylated tetra-antennary N-glycans 

glycan_dictionary_accession : GSD000057 

glytoucan_accession  :  

term_in_sentence : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858] 

definition : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. 

term_xref :  

synonyms :  

function :  

disease_associations : pancreatic cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858]] 

wikipedia :  

essentials_of_glycobiology :

GSD000058

term (main_entry) : Dimeric Lewis x 

glycan_dictionary_accession : GSD000058 

glytoucan_accession  : G79535HZ 

term_in_sentence : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:32957489] 

publication : 32957489|31276881|12062524|15488731|1979361|8737237|17939723|7683631|11384108|11133015|17388629|15483381|12662048|3233598|18618154|21892456 

definition : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] 

term_xref : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 

synonyms : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx 

function : cancer-associated antigen[GlycoEpitope:EP0093] 

disease_associations : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000059

term (main_entry) : Diphosphorylated Man6 

glycan_dictionary_accession : GSD000059 

glytoucan_accession  : G54792LL 

term_in_sentence : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:26503547] 

publication : 26503547 

definition :  

term_xref : GTC:G54792LL|GlycoMotif:GGM.000054

synonyms : Diphosphorylated Man_6 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000060

term (main_entry) : Disialosyl globopentaosylceramide 

glycan_dictionary_accession : GSD000060 

glytoucan_accession  : G97932OH 

term_in_sentence : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142 31339142]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142 31339142]|24637536|25864532|27344728|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983]]|[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311 32567311]|28205070|20663960|18214042 

definition : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:28205070] 

term_xref : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:[https://pubmed.ncbi.nlm.nih.gov/91860287 91860287 91860287]|KEGG:G00181|SugarBind_Ligand:57  

synonyms : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside 

function : promotes metastasis[PMID:28205070] 

disease_associations : prostate cancer[PMID:24637536]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] 

wikipedia :  

essentials_of_glycobiology :

GSD000061

term (main_entry) : Disialyl Gb5 

glycan_dictionary_accession : GSD000061 

glytoucan_accession  : G97932OH 

term_in_sentence : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983]]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983]] 

definition :  

term_xref : GlycoEpitope:EP0098|GTC:G97932OH|CID:[https://pubmed.ncbi.nlm.nih.gov/91860287 91860287 91860287]|SugarBind_Ligand:57|KEGG:G00181  

synonyms :  

function :  

disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] 

wikipedia :  

essentials_of_glycobiology :

GSD000062

term (main_entry) : Disialyl I 

glycan_dictionary_accession : GSD000062 

glytoucan_accession  : G54937EM 

term_in_sentence : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:10640401] 

publication : 10640401 

definition :  

term_xref : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523  

synonyms : disialyl-I 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000063

term (main_entry) : Disialyl Lewis a 

glycan_dictionary_accession : GSD000063 

glytoucan_accession  : G93400AK 

term_in_sentence : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675] 

publication : 12668675|17760270|15231659|12668106|30716533|32050430|22467657 

definition : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:15231659] 

term_xref : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 

synonyms : disialyl Lea 

function : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] 

disease_associations : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] 

wikipedia :  

essentials_of_glycobiology :

GSD000064

term (main_entry) : Disialyl T antigen 

glycan_dictionary_accession : GSD000064 

glytoucan_accession  : G01614ZM 

term_in_sentence : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: 15701648] 

publication : 29113555|17974963|33242079|12645620|15701648|26598643 

definition : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] 

term_xref : GlycoMotif:GGM.000014|GTC:G01614ZM|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027  

synonyms : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen 

function : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000065

term (main_entry) : Disialylated biantennary 

glycan_dictionary_accession : GSD000065 

glytoucan_accession  :  

term_in_sentence : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:8486673] 

publication : 22426998|17171781|25022802|24812685|24780636|26582205|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382 9499382]|22978794|22594947|8486673|20356825|1634621|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096 12966096]|1472054|[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045 24243045]|19579232|27943633 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. 

term_xref :  

synonyms : disialylated diantennary 

function : appears in human transferrin[PMID: [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] 

disease_associations : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382 9499382]] 

wikipedia :  

essentials_of_glycobiology :

GSD000066

term (main_entry) : Disialylated biantennary complex-type 

glycan_dictionary_accession : GSD000066 

glytoucan_accession  :  

term_in_sentence : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:11738084] 

publication : 11738084|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096 12966096]|25124522|19371135 

definition : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. 

term_xref :  

synonyms :  

function : appears in human transferrin[PMID:[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] 

disease_associations : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382 9499382]] 

wikipedia :  

essentials_of_glycobiology :

GSD000067

term (main_entry) : Disialylated fucosylated 

glycan_dictionary_accession : GSD000067 

glytoucan_accession  :  

term_in_sentence : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:17591618] 

publication : 17591618 

definition : A fucosylated glycan with two sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 45

GSD000068

term (main_entry) : Forssman antigen 

glycan_dictionary_accession : GSD000068 

glytoucan_accession  : G80062GG 

term_in_sentence : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:28510705] 

publication : 28510705|31933576|[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301 28134301]|7021748|1802714|7512587|7747818|23325748|268649|31816281|22015168|4147161|2857159|6267170|7293775|13367419|20636540|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829 10460829]]|23255552|2675268|18955372|7020692|31784953|4114942|31273262|6257673|7696847|1916901|11169215|48262|26022515|6175621|31404475|6983878|8381954|[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785 10431785]|3257757|6792413|25039359 

definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789] 

term_xref : GTC:G80062GG |GlycoEpitope:EP0037|CID[https://pubmed.ncbi.nlm.nih.gov/91825690 91825690 91825690]|CHEBI:85789 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 45

GSD000069

term (main_entry) : Forssman glycolipid 

glycan_dictionary_accession : GSD000069 

glytoucan_accession  : G80062GG 

term_in_sentence : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:3040119] 

publication : 3040119|268649|23240079|[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301 28134301]|3495590|1138893|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829 10460829]]|10506200|8855242|1955453|1933935|3355161|6773959|14573676|29898878|[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956 1747956]|11214737|7423202|389939|3871816|6187373|16133832|469271|3753492|2695680|7037611|25703376|23798992|414913|1868069|[https://pubmed.ncbi.nlm.nih.gov/7960243 7960243 7960243] 

definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] 

term_xref : GlycoMotif:GGM.000084|GTC:G80062GG|CID:[https://pubmed.ncbi.nlm.nih.gov/91825690 91825690 91825690]|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 

synonyms : Forssman antigen|Globopentosylceramide 

function : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:3495590] 

disease_associations : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] 

wikipedia :  

essentials_of_glycobiology : Chapter 45

GSD000070

term (main_entry) : Fucose-containing tetraantennary 

glycan_dictionary_accession : GSD000070 

glytoucan_accession  :  

term_in_sentence : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:2550193] 

publication : 2550193 

definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia : https://en.wikipedia.org/wiki/Forssman_antigen 

essentials_of_glycobiology : Chapter 14

GSD000071

term (main_entry) : Fucosyl GM1 

glycan_dictionary_accession : GSD000071 

glytoucan_accession  : G91532KA 

term_in_sentence : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:8068725] 

publication : 6619101|16880505|9089399|29789847|8068725|19556222|1660040|2420639|9076515|15926079|19555091|2541996|16211870|1336587|21174147|14967068|18923900|30021910|16941490|27070150|8305235|10602885|2645049|7993838|10537341|3002616|8336147|15447995|8905401|11714535|9260862|32228455|3315641|8076384|2317201|3680254|6403518 

definition : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] 

term_xref : GTC:G91532KA |GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 

synonyms :  

function :  

disease_associations : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] 

wikipedia :  

essentials_of_glycobiology :

GSD000072

term (main_entry) : Fucosylated asialo-biantennary 

glycan_dictionary_accession : GSD000072 

glytoucan_accession  :  

term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054 2065054]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054 2065054]|17013932 

definition : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. 

term_xref :  

synonyms : fucosylated asialo-diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000073

term (main_entry) : Fucosylated biantennary 

glycan_dictionary_accession : GSD000073 

glytoucan_accession  :  

term_in_sentence : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:17956937] 

publication : 17956937|30525457|1933856 

definition : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms : fucosylated bisialo-diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000074

term (main_entry) : Fucosylated bisialo-biantennary 

glycan_dictionary_accession : GSD000074 

glytoucan_accession  :  

term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054 2065054]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054 2065054] 

definition : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. 

term_xref :  

synonyms : Fucosylated biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000075

term (main_entry) : Fucosylated LDN 

glycan_dictionary_accession : GSD000075 

glytoucan_accession  : G02240AO 

term_in_sentence : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:16403022] 

publication : 16403022|28151933|19545571|22448293 

definition : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] 

term_xref : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 

synonyms : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000076

term (main_entry) : Fucosylated N-glycans 

glycan_dictionary_accession : GSD000076 

glytoucan_accession  :  

term_in_sentence : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858]] 

publication : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858]|31141660|26869352|29790113|31931062 

definition : The fucose from GDP-fucose is transferred to N-linked glycans. 

term_xref :  

synonyms :  

function :  

disease_associations : pancreatic cancer.[PMID: 26869352] 

wikipedia :  

essentials_of_glycobiology :

GSD000077

term (main_entry) : Fucosylated triantennary 

glycan_dictionary_accession : GSD000077 

glytoucan_accession  :  

term_in_sentence : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:2513186] 

publication : 2513186|29642865|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920 7679920]|31110965|2551687|15051952|12943224 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms :  

function : appears in human alpha-fetoprotein (AFP).[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920 7679920]] 

disease_associations : neoplastic diseases of the liver[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920 7679920] ]|hepatocellular carcinoma[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920 7679920]]. 

wikipedia :  

essentials_of_glycobiology : Chapter 43

GSD000078

term (main_entry) : Galabiosylceramide 

glycan_dictionary_accession : GSD000078 

glytoucan_accession  : G67988RO 

term_in_sentence : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:33360824] 

publication : 33360824|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167 29099167]|25582508|2824515|4027258|32854306|32868283|31319156|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250 29530250]|27367163|2564247|27727434|10216186|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829 10460829]]|24992926|23590301|15702404|1854798|14761135|3600200|8603914|8601603|1965141|17400502|3840690|15959771|7930586|7721812|17095952|2500499|3815386|8842706|10746023|3928791|3782065|6440894 

definition : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] 

term_xref : GlycoEpitope:EP0113|GTC:G67988RO|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 

synonyms :  

function :  

disease_associations : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] 

wikipedia :  

essentials_of_glycobiology :

GSD000079

term (main_entry) : Galactosylceramide 

glycan_dictionary_accession : GSD000079 

glytoucan_accession  : G65889KE 

term_in_sentence : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:31393621] 

publication : 31393621|19941861|9883654|33006978|26735924|22032265|18035062|25129050|2802541|1761517|28660574|475780|2302222 

definition :  

term_xref : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061

synonyms : GalCer|Galactocerebroside|LC 

function :  

disease_associations : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] 

wikipedia :  

essentials_of_glycobiology :

GSD000080

term (main_entry) : Galnac disialyl Lc4 (Hexasaccharide) 

glycan_dictionary_accession : GSD000080 

glytoucan_accession  : G33532XU 

term_in_sentence : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983]]] 

publication : 15704108|11278988|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983 12084983]]|7509790 

definition : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID:91857945] 

term_xref : GlycoEpitope:EP0097|GTC:G33532XU|CID:91857945|CHEBI:149360 

synonyms :  

function :  

disease_associations : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] 

wikipedia :  

essentials_of_glycobiology :

GSD000081

term (main_entry) : Gb5 

glycan_dictionary_accession : GSD000081 

glytoucan_accession  : G99053DY 

term_in_sentence : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:25839135] 

publication : 12401210|25839135|31540393|31140679|3028540|3674263|[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142 31339142]|30026902|10721708|30671362|26176557|25039255|24044869|[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311 32567311]|27857717|21491978|24910250|29077212|8014006|27107335|32679486|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956 1747956]|8679447|28352526|11341836|10837462|[https://pubmed.ncbi.nlm.nih.gov/7960243 7960243 7960243]|16158941|3297853|2431136|21734356|8625206|30732055|12716912|20128040|2582447|14659673 

definition : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] 

term_xref : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12

synonyms : Globopentaosylceramide 

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000082

term (main_entry) : GD1 

glycan_dictionary_accession : GSD000082 

glytoucan_accession  : G81983KG 

term_in_sentence : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:31791361] 

publication : 5652802|25345088|31791361|29361370|31234327|30264864|25250137|7528216|31669751|20684311|16306603|10420586|7766692|31614613|26384672|31613991|19210136|8926633|29696051|32300455|7513313|26674302|20336376|24259734|31704237|21067946|30516933|27979707|26345314|30516941|31849452|27789132|30218706|29388611|20177787 

definition :  

term_xref : GlycoMotif:GGM.000105|GTC:G81983KG|CID:91859783|KEGG:G00126  

synonyms : GD1c 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000083

term (main_entry) : GD1a 

glycan_dictionary_accession : GSD000083 

glytoucan_accession  : G46677TE | G45714BQ

term_in_sentence : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: 28899916] 

publication : 28899916|26860251|21930390|32906699|26054879|29951721|11745410|17653976|26119566|21554929|18435913|15342262|26865725|21151139|15716397|21492147|16942752|26973195|24449473|14999485|22735313|20589721|10521808|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125 22929125]|7827024|16897174|25062498|17227759 

definition : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] 

term_xref : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111  

synonyms : GD1alpha 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] 

wikipedia :  

essentials_of_glycobiology :

GSD000084

term (main_entry) : GD1b 

glycan_dictionary_accession : GSD000084 

glytoucan_accession  : G37184KW 

term_in_sentence : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: 27144558] 

publication : 27144558|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332 24859332]|18625966|7945223|32518172|26710925|31837178|20594196|30985655|11511306|1742806|11123278|7685064|2709011|33279873|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125 22929125]|9179156|17964572|8821498|32726962|26560950|2611779|10072058|20030259|16415013|10797556|11342695|8619520|21519903|16199892|23777091|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056 30246056]|10481046 

definition : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] 

term_xref : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000085

term (main_entry) : GD2 

glycan_dictionary_accession : GSD000085 

glytoucan_accession  : G02657AK 

term_in_sentence : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: 25440605] 

publication : 28154831|32002293|32733795|28145567|31500597|31903906|29180536|28415563|25440605|30617136|25604432|30198960|31075227|31721713|30955398|32195035|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202 27304202]|31015228|31653037|31016728|30670592|30613134|29221154|30027525|29442009|31762628|30485077|25642322|[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609 29436609]|29151270|24773917|30612272|27654028|26298772 

definition : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] 

term_xref : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88  

synonyms :  

function :  

disease_associations : breast cancer[PMID:28415563] 

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chatper 35

GSD000086

term (main_entry) : GD3 

glycan_dictionary_accession : GSD000086 

glytoucan_accession  : G98544DH 

term_in_sentence : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: 12531552] 

publication : 30245960|27591028|12531552|29069780|12470841|[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609 29436609]|28295752|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202 27304202]|31138648|27288875|30446565|8721669|3903474|16081368|32743804|24372645|26792897|20890432|25330147|20581115|11174200|16040804|23783008|17368571|11023989|12901230|21807667|7061953|2231782|19423750|22632091|18202973|6392333|15896784|8261439|20052288|12847141|12486096|12118012|19912988|22795094|18655184|17043769|21395555|2472199|19776077 

definition : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] 

term_xref : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062  

synonyms :  

function :  

disease_associations : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000087

term (main_entry) : Globoside 

glycan_dictionary_accession : GSD000087 

glytoucan_accession  : G00061MO 

term_in_sentence : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:10993897] 

publication : 10993897 

definition :  

term_xref : GlycoMotif:GGM.000070|GTC:G00061MO  

synonyms : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000088

term (main_entry) : Globotetraosylceramide 

glycan_dictionary_accession : GSD000088 

glytoucan_accession  : G00061MO 

term_in_sentence : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:28392398] 

publication : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389 30413389]|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240 

definition : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] 

term_xref : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032

synonyms : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K 

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] 

wikipedia :  

essentials_of_glycobiology :  Chapter 11

GSD000089

term (main_entry) : Globotriaosylceramide 

glycan_dictionary_accession : GSD000089 

glytoucan_accession  : G00059MO 

term_in_sentence : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409] 

publication : 32127409|28674962|30875019|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389 30413389]|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250 29530250]|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167 29099167]|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511 

definition : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] 

term_xref : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27  

synonyms : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide 

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] 

wikipedia :  

essentials_of_glycobiology :

GSD000090

term (main_entry) : Glucosylceramide 

glycan_dictionary_accession : GSD000090 

glytoucan_accession  : G71142DF 

term_in_sentence : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] 

publication : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571 

definition : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] 

term_xref : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF

synonyms : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH 

function : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] 

disease_associations : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] 

wikipedia :  

essentials_of_glycobiology : Chapter 31

GSD000091

term (main_entry) : GM1 

glycan_dictionary_accession : GSD000091 

glytoucan_accession  : G48558GR 

term_in_sentence : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] 

publication : 18524657|31761138|36180805|29920238|33859490|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|[https://pubmed.ncbi.nlm.nih.gov/6619101 6619101 6619101] 

definition : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] 

term_xref : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 

synonyms :  GM1 ganglioside|GM1-ganglioside

function :  The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:16267866]

disease_associations : GM1 gangliosidosis (GM1) [PMID: 33859490]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] 

wikipedia : https://en.wikipedia.org/wiki/GM1 

essentials_of_glycobiology :  Chapter 11| Chapter 14

GSD000092

term (main_entry) : GM2 

glycan_dictionary_accession : GSD000092 

glytoucan_accession  : G79389NT 

term_in_sentence : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214] 

publication : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924| 

definition : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] 

term_xref : GlycoMotif:GGM.000095|GTC:G79389NT|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351  

synonyms :  

function :  

disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] 

wikipedia : https://en.wikipedia.org/wiki/GM1_gangliosidoses 

essentials_of_glycobiology : Chapter 11

GSD000093

term (main_entry) : GM3 

glycan_dictionary_accession : GSD000093 

glytoucan_accession  : G91237TK 

term_in_sentence : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813] 

publication : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008| 

definition : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] 

term_xref : GlycoMotif:GGM.000090|GTC:G91237TK|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 

synonyms :  

function : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] 

disease_associations : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] 

wikipedia :  

essentials_of_glycobiology : Chapter 37

GSD000094

term (main_entry) : GM4 

glycan_dictionary_accession : GSD000094 

glytoucan_accession  : G30207PZ 

term_in_sentence : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868] 

publication : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056 30246056]|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798 

definition : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
[CHEBI:63155] 

term_xref : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 

synonyms :  Sialylated GalCer

function :  

disease_associations : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] 

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chapter 15|Chapter 44|Appendix 45A

GSD000095

term (main_entry) : GP1c 

glycan_dictionary_accession : GSD000095 

glytoucan_accession  : G93805MV 

term_in_sentence : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458] 

publication : 1606358|19053458|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858 1695858]|4091974|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875 3064875]|11432974|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845 11831845]|1879553|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494 10699494]|8969459|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286 12031286]|1304332|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776 10564776] 

definition :  

term_xref : GlycoMotif:GGM.000118|GTC:G93805MV

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chapter 14|Chapter 27|Chapter 35|Chapter 45 |Chapter 47|Chapter 49

GSD000096

term (main_entry) : GQ1b 

glycan_dictionary_accession : GSD000096 

glytoucan_accession  : G18625KA 

term_in_sentence : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474] 

publication : 30798387|31186474|26704905|23677659|26984947|24184316|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237 23804237]|9819299|18514410|22189683|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332 24859332] 

definition : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] 

term_xref : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000097

term (main_entry) : GQ1ba 

glycan_dictionary_accession : GSD000097 

glytoucan_accession  : G54733XO 

term_in_sentence : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341] 

publication : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997 

definition :  

term_xref : GlycoMotif:GGM.000116|GTC:G54733XO  

synonyms : GQ1balpha 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000098

term (main_entry) : GQ1c 

glycan_dictionary_accession : GSD000098 

glytoucan_accession  : G99524KA 

term_in_sentence : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] 

publication : 6640289|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858 1695858]|7798936|1729139|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656 2468656]|20368669|2723647|1814411|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875 3064875]|6085330|1613492|17883393|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425 10775425]|8219015|8804704|1384262|7066685|2299192|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831 9613831]|10350354|1304337|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001 9153001]|11959025|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494 10699494]|3942818|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286 12031286]|7361620 

definition : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:91860352] 

term_xref : GlycoMotif:GGM.000117|GTC:G99524KA|CID:91860352|CHEBI:145645|KEGG:G00121 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 46

GSD000099

term (main_entry) : GT1a 

glycan_dictionary_accession : GSD000099 

glytoucan_accession  : G68110IF 

term_in_sentence : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476] 

publication : 12023422|32623212|26197476|9585812|29747820|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237 23804237]|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|8910600|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751 

definition : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] 

term_xref : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000100

term (main_entry) : GT1a alpha 

glycan_dictionary_accession : GSD000100 

glytoucan_accession  : G02149VR 

term_in_sentence : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783] 

publication : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808 

definition :  

term_xref : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128  

synonyms : GT1aa 

function : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

@@ Line 1: / Line 1: @@
-===T antigen===
+===GSD000031===
-[[File:G00031MO.png|thumb|G00031MO]]
+  '''term (main_entry)''' : Blood group A1 (Type 3) <br>
-  '''term (main_entry)''' : T antigen <br>
+  '''glycan_dictionary_accession''' : GSD000031 <br>
-  '''glycan_dictionary_accession''' : GSD000163 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G44060QH G44060QH] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br>
+  '''term_in_sentence''' : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:[https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]] <br>
-  '''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298] <br>
- '''publication''' :[https://pubmed.ncbi.nlm.nih.gov/723127 723127]|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/26615524 26615524]|[https://pubmed.ncbi.nlm.nih.gov/26136575 26136575]|[https://pubmed.ncbi.nlm.nih.gov/19671663 19671663]|[https://pubmed.ncbi.nlm.nih.gov/18551603 18551603]|[https://pubmed.ncbi.nlm.nih.gov/11160729 11160729]|[https://pubmed.ncbi.nlm.nih.gov/22261839 22261839]|[https://pubmed.ncbi.nlm.nih.gov/30758913 30758913]|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/24998850 24998850]|[https://pubmed.ncbi.nlm.nih.gov/1654819 1654819]|[https://pubmed.ncbi.nlm.nih.gov/28039910 28039910]|[https://pubmed.ncbi.nlm.nih.gov/29206210 29206210]|[https://pubmed.ncbi.nlm.nih.gov/32404521 32404521]|[https://pubmed.ncbi.nlm.nih.gov/10555041 10555041]|[https://pubmed.ncbi.nlm.nih.gov/26517398 26517398]|[https://pubmed.ncbi.nlm.nih.gov/2446015 2446015]|[https://pubmed.ncbi.nlm.nih.gov/2998768 2998768]|[https://pubmed.ncbi.nlm.nih.gov/3026642 3026642]|[https://pubmed.ncbi.nlm.nih.gov/18812503 18812503]|[https://pubmed.ncbi.nlm.nih.gov/6092664 6092664]|[https://pubmed.ncbi.nlm.nih.gov/2153691 2153691]|[https://pubmed.ncbi.nlm.nih.gov/8709258 8709258]|[https://pubmed.ncbi.nlm.nih.gov/3009889 3009889]|[https://pubmed.ncbi.nlm.nih.gov/15109748 15109748]| [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/31787742 31787742]|[https://pubmed.ncbi.nlm.nih.gov/27433780 27433780]|[https://pubmed.ncbi.nlm.nih.gov/26017382 26017382]|[https://pubmed.ncbi.nlm.nih.gov/24048785 24048785]|[https://pubmed.ncbi.nlm.nih.gov/26735515 26735515]|[https://pubmed.ncbi.nlm.nih.gov/9224657 9224657]|[https://pubmed.ncbi.nlm.nih.gov/26061652 26061652]|[https://pubmed.ncbi.nlm.nih.gov/29343574 29343574]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708] [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]]|[https://pubmed.ncbi.nlm.nih.gov/23805194 23805194]|[https://pubmed.ncbi.nlm.nih.gov/26751495 26751495]|[https://pubmed.ncbi.nlm.nih.gov/22023388 22023388]|[https://pubmed.ncbi.nlm.nih.gov/15381338 15381338]|[https://pubmed.ncbi.nlm.nih.gov/8249277 8249277]|[https://pubmed.ncbi.nlm.nih.gov/3023660 3023660]|[https://pubmed.ncbi.nlm.nih.gov/25866902 25866902] <br>
+ '''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br>
-  '''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br>
+ '''term_xref''' : GTC:G44060QH|CHEBI:85665|CID:[https://pubmed.ncbi.nlm.nih.gov/91825676 91825676]|GlycoMotif:GGM.000040  <br>
-  '''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009<br>
+ '''synonyms''' : Blood group A1 (type 3)|Blood Group A1 <br>
-  '''synonyms''' : TF antigen <br>
+ '''function''' :  <br>
-  '''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br>
+ '''disease_associations''' :  <br>
-  '''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000032===
+[[File:G62735WZ.png|thumb|G62735WZ]]
+ '''term (main_entry)''' : Blood group A2 (A-associated H type 3) <br>
+ '''glycan_dictionary_accession''' : GSD000032 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G62735WZ G62735WZ] <br>
+ '''term_in_sentence''' : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]]
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]|[https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br>
+ '''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br>
+ '''term_xref''' : CHEBI:152543|CID:[https://pubmed.ncbi.nlm.nih.gov/91852328 91852328]|GlycoMotif:GGM.000041|GTC:G62735WZ <br>
+ '''synonyms''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000033===
+[[File:G31734OS.png|thumb|G31734OS]]
+ '''term (main_entry)''' : Blood group B (Type 1) <br>
+ '''glycan_dictionary_accession''' : GSD000033 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31734OS G31734OS] <br>
+ '''term_in_sentence''' : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633] [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592] [https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]]|[https://pubmed.ncbi.nlm.nih.gov/24749871 24749871]|[https://pubmed.ncbi.nlm.nih.gov/19387828 19387828]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633] [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]]|[https://pubmed.ncbi.nlm.nih.gov/29562255 29562255] <br>
+  '''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br>
+  '''term_xref''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID:[https://pubmed.ncbi.nlm.nih.gov/56927779 56927779]|CHEBI:63242 <br>
+  '''synonyms''' : blood group B type 1 tetrasaccharide <br>
+  '''function''' :  <br>
+  '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
+  '''essentials_of_glycobiology''' :  <br>
-===Tetraantennary===
+===GSD000034===
-  '''term (main_entry)''' : Tetraantennary <br>
+  '''term (main_entry)''' : Blood group B (Type 2) <br>
-  '''glycan_dictionary_accession''' : GSD000164 <br>
+  '''glycan_dictionary_accession''' : GSD000034 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G34881WK G34881WK] <br>
- '''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br>
+  '''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062] [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281] [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]]|[https://pubmed.ncbi.nlm.nih.gov/25154914 25154914]|[https://pubmed.ncbi.nlm.nih.gov/22490318 22490318]|[https://pubmed.ncbi.nlm.nih.gov/22430811 22430811]|[https://pubmed.ncbi.nlm.nih.gov/1463783 1463783]|[https://pubmed.ncbi.nlm.nih.gov/18803208 18803208]|[https://pubmed.ncbi.nlm.nih.gov/7881173 7881173]|[https://pubmed.ncbi.nlm.nih.gov/7697655 7697655]|[https://pubmed.ncbi.nlm.nih.gov/7240157 7240157]|[https://pubmed.ncbi.nlm.nih.gov/1768292 1768292] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062] [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]]|[https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592] [https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]] <br>
-  '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
+  '''definition''' :  <br>
-  '''term_xref''' :  <br>
+  '''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262  <br>
-  '''synonyms''' :  <br>
+  '''synonyms''' : blood group B type 2 <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
-  '''wikipedia''' : https://www.wikidata.org/wiki/Q[https://pubmed.ncbi.nlm.nih.gov/27104888 27104888] <br>
+  '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===Tetraantennary complex-type===
+===GSD000035===
-  '''term (main_entry)''' : Tetraantennary complex-type <br>
+  '''term (main_entry)''' : Blood group B (Type 4) <br>
-  '''glycan_dictionary_accession''' : GSD000165 <br>
+  '''glycan_dictionary_accession''' : GSD000035 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25216QA G25216QA] <br>
-  '''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]] <br>
+  '''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8274017 8274017]|[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]| [https://pubmed.ncbi.nlm.nih.gov/6317691 6317691]|[https://pubmed.ncbi.nlm.nih.gov/23668542 23668542]| [https://pubmed.ncbi.nlm.nih.gov/6088518 6088518]|[https://pubmed.ncbi.nlm.nih.gov/21495009 21495009]|[https://pubmed.ncbi.nlm.nih.gov/1457971 1457971]|[https://pubmed.ncbi.nlm.nih.gov/1783599 1783599]|[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252]|[https://pubmed.ncbi.nlm.nih.gov/11425798 11425798]|[https://pubmed.ncbi.nlm.nih.gov/7522229 7522229]|[https://pubmed.ncbi.nlm.nih.gov/2574992 2574992]|[https://pubmed.ncbi.nlm.nih.gov/3730425 3730425]|[https://pubmed.ncbi.nlm.nih.gov/10200178 10200178]|[https://pubmed.ncbi.nlm.nih.gov/2939068 2939068]|[https://pubmed.ncbi.nlm.nih.gov/21584695 21584695]| [https://pubmed.ncbi.nlm.nih.gov/7524670 7524670]|[https://pubmed.ncbi.nlm.nih.gov/7682847 7682847]|[https://pubmed.ncbi.nlm.nih.gov/2930192 2930192]|[https://pubmed.ncbi.nlm.nih.gov/1726466 1726466]|[https://pubmed.ncbi.nlm.nih.gov/9881746 9881746]|[https://pubmed.ncbi.nlm.nih.gov/11068879 11068879]|[https://pubmed.ncbi.nlm.nih.gov/6704968 6704968]|[https://pubmed.ncbi.nlm.nih.gov/2302846 2302846]| [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/11051207 11051207]|[https://pubmed.ncbi.nlm.nih.gov/10220588 10220588]|[https://pubmed.ncbi.nlm.nih.gov/2813359 2813359]|[https://pubmed.ncbi.nlm.nih.gov/2174368 2174368]|[https://pubmed.ncbi.nlm.nih.gov/21755550 21755550]|[https://pubmed.ncbi.nlm.nih.gov/3571208 3571208]|[https://pubmed.ncbi.nlm.nih.gov/1929437 1929437]|[https://pubmed.ncbi.nlm.nih.gov/3681300 3681300]|[https://pubmed.ncbi.nlm.nih.gov/6581225 6581225]|[https://pubmed.ncbi.nlm.nih.gov/3364983 3364983]|[https://pubmed.ncbi.nlm.nih.gov/2902877 2902877]|[https://pubmed.ncbi.nlm.nih.gov/2297756 2297756]|[https://pubmed.ncbi.nlm.nih.gov/1315684 1315684]|[https://pubmed.ncbi.nlm.nih.gov/6830758 6830758]|[https://pubmed.ncbi.nlm.nih.gov/1998670 1998670] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684] [https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]] <br>
-  '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
+  '''definition''' :  <br>
-  '''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html<br>
+  '''term_xref''' : GlycoMotif:GGM.000087|GTC:G25216QA  <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000036===
+ '''term (main_entry)''' : Blood group H (Type 1) <br>
+ '''glycan_dictionary_accession''' : GSD000036 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00294TN G00294TN] <br>
+ '''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/6309836 6309836]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633] [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]]|[https://pubmed.ncbi.nlm.nih.gov/27431816 27431816]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062] [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]]|[https://pubmed.ncbi.nlm.nih.gov/24219248 24219248]|[https://pubmed.ncbi.nlm.nih.gov/6352465 6352465]|[https://pubmed.ncbi.nlm.nih.gov/8499478 8499478]|[https://pubmed.ncbi.nlm.nih.gov/3348768 3348768]|[https://pubmed.ncbi.nlm.nih.gov/3718924 3718924] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153  <br>
+ '''synonyms''' : H type 1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:153] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000037===
+[[File:G70519XK.png|alt=|thumb|G70519XK]]
+ '''term (main_entry)''' : Blood group H (Type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000037 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G70519XK G70519XK] <br>
+ '''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495] [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495] [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]]|[https://pubmed.ncbi.nlm.nih.gov/8082855 8082855]|[https://pubmed.ncbi.nlm.nih.gov/6177241 6177241]|[https://pubmed.ncbi.nlm.nih.gov/3944092 3944092]|[https://pubmed.ncbi.nlm.nih.gov/21406562 21406562]|[https://pubmed.ncbi.nlm.nih.gov/2410664 2410664]|[https://pubmed.ncbi.nlm.nih.gov/8731502 8731502]|[https://pubmed.ncbi.nlm.nih.gov/6203846 6203846]|[https://pubmed.ncbi.nlm.nih.gov/2238560 2238560]| <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G70519XK|GlycoMotif:GGM.000036  <br>
+ '''synonyms''' : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II <br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000038===
+[[File:G00052MO.png|alt=|thumb|G00052MO]]
+ '''term (main_entry)''' : Blood group H (Type 2) - Lewis y <br>
+ '''glycan_dictionary_accession''' : GSD000038 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00052MO G00052MO] <br>
+ '''term_in_sentence''' : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278] <br>
+ '''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
+ '''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:[https://pubmed.ncbi.nlm.nih.gov/45266908 45266908]|CHEBI:59045|GlycoMotif:GGM.000045  <br>
+ '''synonyms''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br>
+ '''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
+ '''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
+ '''wikipedia''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===Tetrasialylated diantennary===
+===GSD000039===
-  '''term (main_entry)''' : Tetrasialylated diantennary <br>
+  '''term (main_entry)''' : Blood group H (Type 4) <br>
-  '''glycan_dictionary_accession''' : GSD000166 <br>
+  '''glycan_dictionary_accession''' : GSD000039 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98465JN G98465JN] <br>
-  '''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
+  '''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684] [https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11261842 11261842]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684] [https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]]|[https://pubmed.ncbi.nlm.nih.gov/11101633 11101633]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495] [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]] <br>
-  '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br>
+  '''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br>
-  '''term_xref''' :  <br>
+  '''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:[https://pubmed.ncbi.nlm.nih.gov/10260428 10260428]|SugarBind_Ligand:61|CHEBI:65245<br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:61] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===Tn antigen===
+===GSD000040===
-[[File:G57321FI.png|thumb|G57321FI]]
+  '''term (main_entry)''' : C2-O-sLex <br>
-  '''term (main_entry)''' : Tn antigen <br>
+  '''glycan_dictionary_accession''' : GSD000040 <br>
-  '''glycan_dictionary_accession''' : GSD000167 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57321FI G57321FI] <br>
+  '''term_in_sentence''' : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]] <br>
-  '''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]|[https://pubmed.ncbi.nlm.nih.gov/19267921 19267921]|[https://pubmed.ncbi.nlm.nih.gov/21283832 21283832]|[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]|[https://pubmed.ncbi.nlm.nih.gov/17072011 17072011] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br>
+  '''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br>
-  '''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br>
+  '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID:[https://pubmed.ncbi.nlm.nih.gov/91860725 91860725]|KEGG:G10899|CHEBI:155160  <br>
-  '''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br>
   '''synonyms''' :  <br>
-  '''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br>
+  '''function''' :  <br>
-  '''disease_associations''' : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. <br>
+  '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===Triantennary===
+===GSD000041===
-  '''term (main_entry)''' : Triantennary <br>
+[[File:G04416BG.png|thumb|G04416BG]]
-  '''glycan_dictionary_accession''' : GSD000168 <br>
+  '''term (main_entry)''' : Ceramide dihexosyl sulfate <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glycan_dictionary_accession''' : GSD000041 <br>
-  '''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G04416BG G04416BG] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/28129130 28129130]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/8068017 8068017]|[https://pubmed.ncbi.nlm.nih.gov/7783116 7783116]|[https://pubmed.ncbi.nlm.nih.gov/3857231 3857231]|[https://pubmed.ncbi.nlm.nih.gov/20540518 20540518]|[https://pubmed.ncbi.nlm.nih.gov/1706936 1706936]|[https://pubmed.ncbi.nlm.nih.gov/2430615 2430615]|[https://pubmed.ncbi.nlm.nih.gov/8078981 8078981]|[https://pubmed.ncbi.nlm.nih.gov/2211711 2211711]|[https://pubmed.ncbi.nlm.nih.gov/6767476 6767476]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/2597120 2597120]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/20619452 20619452]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/1924399 1924399]|[https://pubmed.ncbi.nlm.nih.gov/6643471 6643471]|[https://pubmed.ncbi.nlm.nih.gov/31809011 31809011]|[https://pubmed.ncbi.nlm.nih.gov/30042045 30042045]|[https://pubmed.ncbi.nlm.nih.gov/2477056 2477056]|[https://pubmed.ncbi.nlm.nih.gov/7882496 7882496]|[https://pubmed.ncbi.nlm.nih.gov/2430614 2430614]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/2426141 2426141]|[https://pubmed.ncbi.nlm.nih.gov/2065052 2065052]|[https://pubmed.ncbi.nlm.nih.gov/28988716 28988716]|[https://pubmed.ncbi.nlm.nih.gov/31144994 31144994]| [https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215] <br>
+  '''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] <br>
-  '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
+  '''publication''' : 818074 <br>
-  '''term_xref''' :  <br>
+  '''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/<nowiki>] </nowiki><br>
+  '''term_xref''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
@@ Line 92: / Line 170: @@
-===Triantennary complex===
+===GSD000043===
-  '''term (main_entry)''' : Triantennary complex <br>
+  '''term (main_entry)''' : Chondroitin sulfate <br>
-  '''glycan_dictionary_accession''' : GSD000169 <br>
+  '''glycan_dictionary_accession''' : GSD000043 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br>
+  '''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588] [https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]]|[https://pubmed.ncbi.nlm.nih.gov/31322324 31322324]|[https://pubmed.ncbi.nlm.nih.gov/15044389 15044389]|[https://pubmed.ncbi.nlm.nih.gov/16372382 16372382]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8299583 8299583]|[https://pubmed.ncbi.nlm.nih.gov/1555586 1555586]|[https://pubmed.ncbi.nlm.nih.gov/7509658 7509658]|[https://pubmed.ncbi.nlm.nih.gov/1569060 1569060]|[https://pubmed.ncbi.nlm.nih.gov/16261636 16261636] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27526113 27526113] [https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]]|[https://pubmed.ncbi.nlm.nih.gov/27194526 27194526]|[https://pubmed.ncbi.nlm.nih.gov/26980567 26980567]|[https://pubmed.ncbi.nlm.nih.gov/28847361 28847361]|[https://pubmed.ncbi.nlm.nih.gov/24413804 24413804]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297] [https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]]|[https://pubmed.ncbi.nlm.nih.gov/29600622 29600622]|[https://pubmed.ncbi.nlm.nih.gov/25129732 25129732]|[https://pubmed.ncbi.nlm.nih.gov/31317901 31317901]|[https://pubmed.ncbi.nlm.nih.gov/29181550 29181550]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530] [https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]]|[https://pubmed.ncbi.nlm.nih.gov/22265655 22265655]|[https://pubmed.ncbi.nlm.nih.gov/25756648 25756648]|[https://pubmed.ncbi.nlm.nih.gov/29402610 29402610]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217] [https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]]|[https://pubmed.ncbi.nlm.nih.gov/20236040 20236040]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940] [https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]]|[https://pubmed.ncbi.nlm.nih.gov/30824935 30824935]|[https://pubmed.ncbi.nlm.nih.gov/26572336 26572336]|[https://pubmed.ncbi.nlm.nih.gov/31207331 31207331]|[https://pubmed.ncbi.nlm.nih.gov/21110089 21110089]|[https://pubmed.ncbi.nlm.nih.gov/30599999 30599999]|[https://pubmed.ncbi.nlm.nih.gov/20399897 20399897]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567] [https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]]|[https://pubmed.ncbi.nlm.nih.gov/19388612 19388612]|[https://pubmed.ncbi.nlm.nih.gov/23186102 23186102]|[https://pubmed.ncbi.nlm.nih.gov/31494830 31494830]|[https://pubmed.ncbi.nlm.nih.gov/28982096 28982096]|[https://pubmed.ncbi.nlm.nih.gov/30241863 30241863]|[https://pubmed.ncbi.nlm.nih.gov/30295666 30295666]|[https://pubmed.ncbi.nlm.nih.gov/25366475 25366475]|[https://pubmed.ncbi.nlm.nih.gov/20521042 20521042]|[https://pubmed.ncbi.nlm.nih.gov/29456007 29456007]|[https://pubmed.ncbi.nlm.nih.gov/31304829 31304829]|[https://pubmed.ncbi.nlm.nih.gov/18661362 18661362]|[https://pubmed.ncbi.nlm.nih.gov/28576008 28576008]|[https://pubmed.ncbi.nlm.nih.gov/29494632 29494632]|[https://pubmed.ncbi.nlm.nih.gov/30016441 30016441]|[https://pubmed.ncbi.nlm.nih.gov/26906924 26906924]|[https://pubmed.ncbi.nlm.nih.gov/24861964 24861964]|[https://pubmed.ncbi.nlm.nih.gov/23774590 23774590]|[https://pubmed.ncbi.nlm.nih.gov/31887904 31887904]|[https://pubmed.ncbi.nlm.nih.gov/31339761 31339761]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856] [https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]]|[https://pubmed.ncbi.nlm.nih.gov/26957048 26957048]|[https://pubmed.ncbi.nlm.nih.gov/29625000 29625000] <br>
-  '''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
+  '''definition''' : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br>
-  '''term_xref''' : CHEBI:156252 <br>
+  '''term_xref''' : CHEBI:37397|CID:24766 <br>
-  '''synonyms''' : Triantennary complex-type <br>
+  '''synonyms''' : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000044===
+ '''term (main_entry)''' : cisGM1 <br>
+ '''glycan_dictionary_accession''' : GSD000044 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G03277YI G03277YI] <br>
+ '''term_in_sentence''' : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923] <br>
+ '''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br>
+ '''term_xref''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID:[https://pubmed.ncbi.nlm.nih.gov/91850212 91850212]|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
+ '''synonyms''' : GM1b <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Influenza[SugarBind_Ligand:92] <br>
+ '''wikipedia''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23]<br>
-===Triantennary N-glycans===
+===GSD000045===
-  '''term (main_entry)''' : Triantennary N-glycans <br>
+  '''term (main_entry)''' : Complex-type N-glycans <br>
-  '''glycan_dictionary_accession''' : GSD000170 <br>
+  '''glycan_dictionary_accession''' : GSD000045 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] <br>
+  '''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29399163 29399163]|[https://pubmed.ncbi.nlm.nih.gov/22325877 22325877]|[https://pubmed.ncbi.nlm.nih.gov/18439991 18439991]|[https://pubmed.ncbi.nlm.nih.gov/24873509 24873509]|[https://pubmed.ncbi.nlm.nih.gov/11454001 11454001] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29902282 29902282]|[https://pubmed.ncbi.nlm.nih.gov/29212795 29212795]|[https://pubmed.ncbi.nlm.nih.gov/29343819 29343819]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/26745022 26745022]|[https://pubmed.ncbi.nlm.nih.gov/18399796 18399796]|[https://pubmed.ncbi.nlm.nih.gov/16825488 16825488]|[https://pubmed.ncbi.nlm.nih.gov/21964725 21964725]|[https://pubmed.ncbi.nlm.nih.gov/15864431 15864431]|[https://pubmed.ncbi.nlm.nih.gov/22890903 22890903]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/28039392 28039392]|[https://pubmed.ncbi.nlm.nih.gov/19426135 19426135]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/16794314 16794314]|[https://pubmed.ncbi.nlm.nih.gov/19806620 19806620]|[https://pubmed.ncbi.nlm.nih.gov/22975979 22975979]|[https://pubmed.ncbi.nlm.nih.gov/25931033 25931033]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/19129634 19129634]|[https://pubmed.ncbi.nlm.nih.gov/19129628 19129628]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/31021709 31021709]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/28091941 28091941]|[https://pubmed.ncbi.nlm.nih.gov/23115339 23115339]|[https://pubmed.ncbi.nlm.nih.gov/20829342 20829342]|[https://pubmed.ncbi.nlm.nih.gov/27304954 27304954]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617] [https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]]|[https://pubmed.ncbi.nlm.nih.gov/21802690 21802690]|[https://pubmed.ncbi.nlm.nih.gov/29725121 29725121]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26098720 26098720]|[https://pubmed.ncbi.nlm.nih.gov/31080188 31080188]|[https://pubmed.ncbi.nlm.nih.gov/1930135 1930135]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/30844485 30844485]|[https://pubmed.ncbi.nlm.nih.gov/24014058 24014058]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583] <br>
-  '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
+  '''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
   '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : Involved in protein stability.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
+===GSD000046===
+ '''term (main_entry)''' : Core 2 <br>
+ '''glycan_dictionary_accession''' : GSD000046 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00033MO G00033MO] <br>
+ '''term_in_sentence''' : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]|[https://pubmed.ncbi.nlm.nih.gov/30315106 30315106]|[https://pubmed.ncbi.nlm.nih.gov/23640779 23640779]|[https://pubmed.ncbi.nlm.nih.gov/26677400 26677400] <br>
+ '''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br>
+ '''term_xref''' : GTC:G00033MO|CID:[https://pubmed.ncbi.nlm.nih.gov/52921656 52921656]|CHEBI:62158  <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
@@ Line 122: / Line 230: @@
-===Triantennary sialylated===
+===GSD000047===
-  '''term (main_entry)''' : Triantennary sialylated <br>
+  '''term (main_entry)''' : Core 3 <br>
-  '''glycan_dictionary_accession''' : GSD000171 <br>
+  '''glycan_dictionary_accession''' : GSD000047 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00035MO G00035MO] <br>
-  '''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] <br>
+  '''term_in_sentence''' : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]|[https://pubmed.ncbi.nlm.nih.gov/31964828 31964828]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/27936604 27936604]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/21538882 21538882]|[https://pubmed.ncbi.nlm.nih.gov/7579793 7579793]|[https://pubmed.ncbi.nlm.nih.gov/7613477 7613477]|[https://pubmed.ncbi.nlm.nih.gov/2223825 2223825]|[https://pubmed.ncbi.nlm.nih.gov/3539023 3539023]|[https://pubmed.ncbi.nlm.nih.gov/3674882 3674882] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]|[https://pubmed.ncbi.nlm.nih.gov/27259834 27259834]|[https://pubmed.ncbi.nlm.nih.gov/27143302 27143302]| <br>
-  '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+  '''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br>
-  '''term_xref''' :  <br>
+  '''term_xref''' : GTC:G00035MO|CID:[https://pubmed.ncbi.nlm.nih.gov/25061208 25061208]|CHEBI:71344  <br>
   '''synonyms''' :  <br>
-  '''function''' : Appears in human serotransferrin.[PMID: 3979568] <br>
+  '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
-===Triantennary trisialylated fucosylated===
+===GSD000048===
-  '''term (main_entry)''' : Triantennary trisialylated fucosylated <br>
+  '''term (main_entry)''' : Core 4 <br>
-  '''glycan_dictionary_accession''' : GSD000172 <br>
+  '''glycan_dictionary_accession''' : GSD000048 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00037MO G00037MO] <br>
-  '''term_in_sentence''' : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
+  '''term_in_sentence''' : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]|[https://pubmed.ncbi.nlm.nih.gov/10747980 10747980]| <br>
-  '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. <br>
+  '''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br>
-  '''term_xref''' :  <br>
+  '''term_xref''' : GTC:G00037MO| CID:[https://pubmed.ncbi.nlm.nih.gov/25229562 25229562]|CHEBI:71341 <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8]<br>
+===GSD000049===
+[[File:G78059CC.png|thumb|G78059CC]]
+  '''term (main_entry)''' : Core-fucosylated <br>
+ '''glycan_dictionary_accession''' : GSD000049 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
+ '''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868] [https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974] [https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453] [https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014] [https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267] [https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672] [https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]]|[https://pubmed.ncbi.nlm.nih.gov/28674882 28674882]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/27798819 27798819]|[https://pubmed.ncbi.nlm.nih.gov/32044029 32044029]|[https://pubmed.ncbi.nlm.nih.gov/30962950 30962950]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/30907281 30907281]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617] [https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]]|[https://pubmed.ncbi.nlm.nih.gov/29571940 29571940]|[https://pubmed.ncbi.nlm.nih.gov/28800497 28800497]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/29733746 29733746]|[https://pubmed.ncbi.nlm.nih.gov/31623829 31623829]|[https://pubmed.ncbi.nlm.nih.gov/28768188 28768188]|[https://pubmed.ncbi.nlm.nih.gov/26897254 26897254]|[https://pubmed.ncbi.nlm.nih.gov/31451706 31451706]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868] [https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]]|[https://pubmed.ncbi.nlm.nih.gov/29427759 29427759]|[https://pubmed.ncbi.nlm.nih.gov/28982386 28982386]|[https://pubmed.ncbi.nlm.nih.gov/26587313 26587313]|[https://pubmed.ncbi.nlm.nih.gov/30940702 30940702]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974] [https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]]|[https://pubmed.ncbi.nlm.nih.gov/31249452 31249452]|[https://pubmed.ncbi.nlm.nih.gov/27282921 27282921]|[https://pubmed.ncbi.nlm.nih.gov/31229844 31229844]|[https://pubmed.ncbi.nlm.nih.gov/30445455 30445455]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/24732908 24732908]|[https://pubmed.ncbi.nlm.nih.gov/29209018 29209018]|[https://pubmed.ncbi.nlm.nih.gov/26965517 26965517]|[https://pubmed.ncbi.nlm.nih.gov/28609658 28609658]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453] [https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]]|[https://pubmed.ncbi.nlm.nih.gov/25573275 25573275]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014] [https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]]|[https://pubmed.ncbi.nlm.nih.gov/19218400 19218400]|[https://pubmed.ncbi.nlm.nih.gov/27012207 27012207]|[https://pubmed.ncbi.nlm.nih.gov/27139574 27139574]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267] [https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]]|[https://pubmed.ncbi.nlm.nih.gov/25861849 25861849]|[https://pubmed.ncbi.nlm.nih.gov/32561391 32561391]|[https://pubmed.ncbi.nlm.nih.gov/21374780 21374780]|[https://pubmed.ncbi.nlm.nih.gov/31669139 31669139]|[https://pubmed.ncbi.nlm.nih.gov/25732060 25732060]|[https://pubmed.ncbi.nlm.nih.gov/29408166 29408166]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672] [https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]]|[https://pubmed.ncbi.nlm.nih.gov/30472795 30472795]|[https://pubmed.ncbi.nlm.nih.gov/30614075 30614075]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/25664929 25664929] <br>
+ '''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006<nowiki>]. </nowiki><br>
+ '''term_xref''' : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]]]|CHEBI:70967|CHEBI:156499 <br>
+ '''synonyms''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br>
+ '''function''' : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] <br>
+ '''disease_associations''' : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8] <br>
-===Trifucosyl Lewis b antigen===
+===GSD000050===
-[[File:G74578MX.png|thumb|G74578MX]]
+  '''term (main_entry)''' : Core-fucosylated biantennary <br>
-  '''term (main_entry)''' : Trifucosyl Lewis b antigen <br>
+  '''glycan_dictionary_accession''' : GSD000050 <br>
-  '''glycan_dictionary_accession''' : GSD000173 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74578MX G74578MX] <br>
+  '''term_in_sentence''' : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]] <br>
-  '''term_in_sentence''' : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:[https://pubmed.ncbi.nlm.nih.gov/1735443 1735443]] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/22256781 22256781]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/25855029 25855029]|[https://pubmed.ncbi.nlm.nih.gov/10529240 10529240]|[https://pubmed.ncbi.nlm.nih.gov/26544759 26544759]|[https://pubmed.ncbi.nlm.nih.gov/8206921 8206921]|[https://pubmed.ncbi.nlm.nih.gov/33149259 33149259]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
- '''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br>
+  '''term_xref''' : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]]]|CHEBI:70967|CHEBI:156499 <br>
-  '''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br>
+  '''synonyms''' : core-fucosylated diantennary <br>
-  '''synonyms''' : trifucosyl-Leb antigen <br>
+  '''function''' :  <br>
-  '''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br>
+  '''disease_associations''' :  <br>
-  '''disease_associations''' : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8] <br>
-===Trifucosyl lewis y===
+===GSD000051===
-[[File:G74917JX.png|thumb|G74917JX]]
+  '''term (main_entry)''' : Core-fucosylated biantennary complex-type <br>
-  '''term (main_entry)''' : Trifucosyl lewis y <br>
+  '''glycan_dictionary_accession''' : GSD000051 <br>
-  '''glycan_dictionary_accession''' : GSD000174 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74917JX G74917JX] <br>
+  '''term_in_sentence''' : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10731668 10731668]] <br>
-  '''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10731668 10731668] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269]<br>
+  '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
-  '''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br>
+  '''term_xref''' : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232] [https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]]]|CHEBI:70967|CHEBI:156499  <br>
-  '''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332  <br>
+  '''synonyms''' : core fucosylated diantennary complex-type <br>
-  '''synonyms''' : trifucosyl Ley <br>
   '''function''' :  <br>
-  '''disease_associations''' : colonic adenocarcinomia[GlycoEpitope: EP0094] <br>
+  '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===Trimannosyl core===
+===GSD000052===
-  '''term (main_entry)''' : Trimannosyl core <br>
+[[File:G11148DZ.png|thumb|G11148DZ]]
-  '''glycan_dictionary_accession''' : GSD000175 <br>
+  '''term (main_entry)''' : Cyclic sialyl 6-sulfo Lewis x <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glycan_dictionary_accession''' : GSD000052 <br>
-  '''term_in_sentence''' : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] <br>
+  '''glytoucan_accession ''' :  [https://www.glygen.org/glycan/G11148DZ G11148DZ]<br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18320567 18320567]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/26821880 26821880]|[https://pubmed.ncbi.nlm.nih.gov/2477227 2477227]|[https://pubmed.ncbi.nlm.nih.gov/6213618 6213618]|[https://pubmed.ncbi.nlm.nih.gov/31747570 31747570]|[https://pubmed.ncbi.nlm.nih.gov/29273674 29273674]|[https://pubmed.ncbi.nlm.nih.gov/31064325 31064325]|[https://pubmed.ncbi.nlm.nih.gov/1291063 1291063]|[https://pubmed.ncbi.nlm.nih.gov/28353332 28353332]|[https://pubmed.ncbi.nlm.nih.gov/1421754 1421754]|[https://pubmed.ncbi.nlm.nih.gov/29666272 29666272]|[https://pubmed.ncbi.nlm.nih.gov/11421342 11421342]|[https://pubmed.ncbi.nlm.nih.gov/15648688 15648688]|[https://pubmed.ncbi.nlm.nih.gov/28179475 28179475]|[https://pubmed.ncbi.nlm.nih.gov/28903882 28903882]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/9455915 9455915]|[https://pubmed.ncbi.nlm.nih.gov/22768188 22768188]|[https://pubmed.ncbi.nlm.nih.gov/9254048 9254048]|[https://pubmed.ncbi.nlm.nih.gov/8721739 8721739]|[https://pubmed.ncbi.nlm.nih.gov/2249985 2249985]|[https://pubmed.ncbi.nlm.nih.gov/22933239 22933239]|[https://pubmed.ncbi.nlm.nih.gov/25629585 25629585]|[https://pubmed.ncbi.nlm.nih.gov/24489949 24489949]|[https://pubmed.ncbi.nlm.nih.gov/2981047 2981047]|[https://pubmed.ncbi.nlm.nih.gov/11067815 11067815]|[https://pubmed.ncbi.nlm.nih.gov/1729985 1729985]|[https://pubmed.ncbi.nlm.nih.gov/1710649 1710649]|[https://pubmed.ncbi.nlm.nih.gov/16672288 16672288]|[https://pubmed.ncbi.nlm.nih.gov/2719668 2719668]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/23025485 23025485]|[https://pubmed.ncbi.nlm.nih.gov/22500028 22500028]|[https://pubmed.ncbi.nlm.nih.gov/10409642 10409642]|[https://pubmed.ncbi.nlm.nih.gov/1325461 1325461]|[https://pubmed.ncbi.nlm.nih.gov/23136055 23136055]|[https://pubmed.ncbi.nlm.nih.gov/23085445 23085445]|[https://pubmed.ncbi.nlm.nih.gov/21656680 21656680]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293]|[https://pubmed.ncbi.nlm.nih.gov/22132163 22132163]|[https://pubmed.ncbi.nlm.nih.gov/1425696 1425696]|[https://pubmed.ncbi.nlm.nih.gov/20696712 20696712]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/15084511 15084511]|[https://pubmed.ncbi.nlm.nih.gov/18633282 18633282]|[https://pubmed.ncbi.nlm.nih.gov/15814299 15814299] <br>
+  '''term_in_sentence''' : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]] <br>
-  '''definition''' : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/31222115 31222115]|[https://pubmed.ncbi.nlm.nih.gov/9990070 9990070]|[https://pubmed.ncbi.nlm.nih.gov/23088960 23088960] <br>
-  '''term_xref''' :  <br>
+  '''definition''' :  <br>
+  '''term_xref''' :  GlycoEpitope:EP0017|CID:[https://pubmed.ncbi.nlm.nih.gov/91858084 91858084]|CHEBI:147484<br>
   '''synonyms''' :  <br>
-  '''function''' :  <br>
+  '''function''' : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
@@ Line 199: / Line 322: @@
-===Trisialylated===
+===GSD000053===
-  '''term (main_entry)''' : Trisialylated <br>
+  '''term (main_entry)''' : Cytolipin R <br>
-  '''glycan_dictionary_accession''' : GSD000176 <br>
+  '''glycan_dictionary_accession''' : GSD000053 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br>
-  '''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]] <br>
+  '''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]| [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832] <br>
+  '''publication''' : 893368|[https://pubmed.ncbi.nlm.nih.gov/4375678 4375678]|51702|186204|[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]|[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]|[https://pubmed.ncbi.nlm.nih.gov/24174198 24174198]|[https://pubmed.ncbi.nlm.nih.gov/6072378 6072378]|389925|[https://pubmed.ncbi.nlm.nih.gov/7054174 7054174] <br>
- '''definition''' : A glycan with three sialic acid components. <br>
+ '''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]] <br>
- '''term_xref''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID:[https://pubmed.ncbi.nlm.nih.gov/91855936 91855936]|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17  <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000054===
+ '''term (main_entry)''' : Dermatan sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000054 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27526113 27526113] [https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]]|[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297] [https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]]|[https://pubmed.ncbi.nlm.nih.gov/26164146 26164146]|[https://pubmed.ncbi.nlm.nih.gov/30869126 30869126]|[https://pubmed.ncbi.nlm.nih.gov/7789716 7789716]|[https://pubmed.ncbi.nlm.nih.gov/8597249 8597249]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856] [https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530] [https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217] [https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]]|[https://pubmed.ncbi.nlm.nih.gov/12213784 12213784]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567] [https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]]|[https://pubmed.ncbi.nlm.nih.gov/31455633 31455633]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940] [https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]]|[https://pubmed.ncbi.nlm.nih.gov/19075609 19075609]|[https://pubmed.ncbi.nlm.nih.gov/31071403 31071403]|[https://pubmed.ncbi.nlm.nih.gov/15078125 15078125]|[https://pubmed.ncbi.nlm.nih.gov/18661328 18661328]|[https://pubmed.ncbi.nlm.nih.gov/20581662 20581662]|[https://pubmed.ncbi.nlm.nih.gov/17239765 17239765]|[https://pubmed.ncbi.nlm.nih.gov/15749837 15749837]|[https://pubmed.ncbi.nlm.nih.gov/2777747 2777747]|[https://pubmed.ncbi.nlm.nih.gov/20632047 20632047]|[https://pubmed.ncbi.nlm.nih.gov/8930750 8930750]|[https://pubmed.ncbi.nlm.nih.gov/7762784 7762784]|[https://pubmed.ncbi.nlm.nih.gov/31006321 31006321]|[https://pubmed.ncbi.nlm.nih.gov/26876822 26876822]|[https://pubmed.ncbi.nlm.nih.gov/1522290 1522290]|131009|[https://pubmed.ncbi.nlm.nih.gov/26986023 26986023]|[https://pubmed.ncbi.nlm.nih.gov/8161353 8161353]|[https://pubmed.ncbi.nlm.nih.gov/15315969 15315969]|[https://pubmed.ncbi.nlm.nih.gov/12543559 12543559]|[https://pubmed.ncbi.nlm.nih.gov/30637950 30637950]|[https://pubmed.ncbi.nlm.nih.gov/2525357 2525357]|[https://pubmed.ncbi.nlm.nih.gov/18156656 18156656]|[https://pubmed.ncbi.nlm.nih.gov/9692613 9692613]|[https://pubmed.ncbi.nlm.nih.gov/9200333 9200333]|[https://pubmed.ncbi.nlm.nih.gov/19661164 19661164]|[https://pubmed.ncbi.nlm.nih.gov/2299256 2299256]|[https://pubmed.ncbi.nlm.nih.gov/16075147 16075147]|[https://pubmed.ncbi.nlm.nih.gov/1126924 1126924]|[https://pubmed.ncbi.nlm.nih.gov/9774430 9774430]|[https://pubmed.ncbi.nlm.nih.gov/8537360 8537360]|[https://pubmed.ncbi.nlm.nih.gov/15563459 15563459]|[https://pubmed.ncbi.nlm.nih.gov/21077227 21077227]|[https://pubmed.ncbi.nlm.nih.gov/23275130 23275130]|[https://pubmed.ncbi.nlm.nih.gov/17137817 17137817]|[https://pubmed.ncbi.nlm.nih.gov/6447930 6447930]|[https://pubmed.ncbi.nlm.nih.gov/6209270 6209270] <br>
+ '''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] <br>
+ '''term_xref''' : CHEBI:18376|CID:32756 <br>
+ '''synonyms''' : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate <br>
+ '''function''' : Wound healing[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453034/ Chapter 7]]|maintain the structure of the dermis.[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453056/ Chapter 41]] <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
@@ Line 214: / Line 352: @@
-===Trisialylated complex-type oligosaccharide-alditols===
+===GSD000055===
-  '''term (main_entry)''' : Trisialylated complex-type oligosaccharide-alditols <br>
+  '''term (main_entry)''' : Desialylated <br>
-  '''glycan_dictionary_accession''' : GSD000177 <br>
+  '''glycan_dictionary_accession''' : GSD000055 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] <br>
+  '''term_in_sentence''' : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3571205 3571205] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30015642 30015642]|[https://pubmed.ncbi.nlm.nih.gov/26168491 26168491]|[https://pubmed.ncbi.nlm.nih.gov/29492899 29492899]|[https://pubmed.ncbi.nlm.nih.gov/31774586 31774586]|[https://pubmed.ncbi.nlm.nih.gov/32321401 32321401]|[https://pubmed.ncbi.nlm.nih.gov/23780974 23780974]|[https://pubmed.ncbi.nlm.nih.gov/7600681 7600681]|[https://pubmed.ncbi.nlm.nih.gov/18045697 18045697]|[https://pubmed.ncbi.nlm.nih.gov/1450583 1450583]|[https://pubmed.ncbi.nlm.nih.gov/4137057 4137057]|[https://pubmed.ncbi.nlm.nih.gov/28911304 28911304]|[https://pubmed.ncbi.nlm.nih.gov/27562992 27562992]|[https://pubmed.ncbi.nlm.nih.gov/29950245 29950245]|[https://pubmed.ncbi.nlm.nih.gov/31978220 31978220]|[https://pubmed.ncbi.nlm.nih.gov/2408573 2408573]|[https://pubmed.ncbi.nlm.nih.gov/8612720 8612720]|[https://pubmed.ncbi.nlm.nih.gov/10910970 10910970]|[https://pubmed.ncbi.nlm.nih.gov/27195066 27195066]|[https://pubmed.ncbi.nlm.nih.gov/1434544 1434544]|[https://pubmed.ncbi.nlm.nih.gov/22175031 22175031]|[https://pubmed.ncbi.nlm.nih.gov/24517196 24517196]|[https://pubmed.ncbi.nlm.nih.gov/29794068 29794068]|[https://pubmed.ncbi.nlm.nih.gov/30101537 30101537]|[https://pubmed.ncbi.nlm.nih.gov/18972200 18972200]|[https://pubmed.ncbi.nlm.nih.gov/1478792 1478792]|[https://pubmed.ncbi.nlm.nih.gov/4440781 4440781]|[https://pubmed.ncbi.nlm.nih.gov/21229239 21229239]|[https://pubmed.ncbi.nlm.nih.gov/30844664 30844664]|[https://pubmed.ncbi.nlm.nih.gov/31351722 31351722]|[https://pubmed.ncbi.nlm.nih.gov/31330845 31330845]|[https://pubmed.ncbi.nlm.nih.gov/1872910 1872910] <br>
-  '''definition''' :  <br>
+  '''definition''' : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated<nowiki>] </nowiki><br>
   '''term_xref''' :  <br>
   '''synonyms''' :  <br>
@@ Line 229: / Line 367: @@
-===Trisialylated diantennary===
+===GSD000056===
-  '''term (main_entry)''' : Trisialylated diantennary <br>
+  '''term (main_entry)''' : Desialylated tetrasaccharide <br>
-  '''glycan_dictionary_accession''' : GSD000178 <br>
+  '''glycan_dictionary_accession''' : GSD000056 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
+  '''term_in_sentence''' : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8384526 8384526]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8384526 8384526] <br>
-  '''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br>
+  '''definition''' : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  <br>
   '''term_xref''' :  <br>
   '''synonyms''' :  <br>
@@ Line 241: / Line 379: @@
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
-===Trisialylated triantennary===
+===GSD000057===
-  '''term (main_entry)''' : Trisialylated triantennary <br>
+  '''term (main_entry)''' : Difucosylated tetra-antennary N-glycans <br>
-  '''glycan_dictionary_accession''' : GSD000179 <br>
+  '''glycan_dictionary_accession''' : GSD000057 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br>
+  '''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/8900952 8900952] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br>
-  '''definition''' : A triantennry glycan with three sialic acid components. <br>
+  '''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br>
   '''term_xref''' :  <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : pancreatic cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]] <br>
+ '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===VIM-2===
+===GSD000058===
-[[File:G22418PV.png|thumb|G22418PV]]
+  '''term (main_entry)''' : Dimeric Lewis x <br>
-  '''term (main_entry)''' : VIM-2 <br>
+  '''glycan_dictionary_accession''' : GSD000058 <br>
-  '''glycan_dictionary_accession''' : GSD000180 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79535HZ G79535HZ] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G22418PV G22418PV] <br>
+  '''term_in_sentence''' : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]] <br>
-  '''term_in_sentence''' : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/12062524 12062524]|[https://pubmed.ncbi.nlm.nih.gov/15488731 15488731]|[https://pubmed.ncbi.nlm.nih.gov/1979361 1979361]|[https://pubmed.ncbi.nlm.nih.gov/8737237 8737237]|[https://pubmed.ncbi.nlm.nih.gov/17939723 17939723]|[https://pubmed.ncbi.nlm.nih.gov/7683631 7683631]|[https://pubmed.ncbi.nlm.nih.gov/11384108 11384108]|[https://pubmed.ncbi.nlm.nih.gov/11133015 11133015]|[https://pubmed.ncbi.nlm.nih.gov/17388629 17388629]|[https://pubmed.ncbi.nlm.nih.gov/15483381 15483381]|[https://pubmed.ncbi.nlm.nih.gov/12662048 12662048]|[https://pubmed.ncbi.nlm.nih.gov/3233598 3233598]|[https://pubmed.ncbi.nlm.nih.gov/18618154 18618154]|[https://pubmed.ncbi.nlm.nih.gov/21892456 21892456] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br>
+  '''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br>
-  '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br>
+  '''term_xref''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID:[https://pubmed.ncbi.nlm.nih.gov/50909845 50909845]|CHEBI:61325|GlycoMotif:GGM.000031 <br>
-  '''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033  <br>
+  '''synonyms''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br>
-  '''synonyms''' :  <br>
+  '''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br>
-  '''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br>
+  '''disease_associations''' : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] <br>
-  '''disease_associations''' : chronic myelogenous leukemia.[GlycoEpitope:EP0019] <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-==Terms (by Glycan Dictionary Accessions)==
+===GSD000059===
-===GSD000001===
+  '''term (main_entry)''' : Diphosphorylated Man6 <br>
-  '''term (main_entry)''' : 2,6-Branched O-mannose <br>
+  '''glycan_dictionary_accession''' : GSD000059 <br>
-  '''glycan_dictionary_accession''' : GSD000001 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54792LL G54792LL] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06953DR G06953DR] <br>
+  '''term_in_sentence''' : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26503547 26503547]] <br>
-  '''term_in_sentence''' : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/26503547 26503547] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/10469154 10469154] <br>
+  '''definition''' :  <br>
-  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] <br>
+  '''term_xref''' : GTC:G54792LL|GlycoMotif:GGM.000054<br>
-  '''term_xref''' : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR  <br>
+  '''synonyms''' : Diphosphorylated Man_6 <br>
-  '''synonyms''' : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
@@ Line 290: / Line 427: @@
-===GSD000002===
+===GSD000060===
-  '''term (main_entry)''' : 2,6-sialyl-Sulfo-LN <br>
+  '''term (main_entry)''' : Disialosyl globopentaosylceramide <br>
-  '''glycan_dictionary_accession''' : GSD000002 <br>
+  '''glycan_dictionary_accession''' : GSD000060 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41145LF G41145LF] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br>
-  '''term_in_sentence''' : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
+  '''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142] [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142] [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]]|[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]|[https://pubmed.ncbi.nlm.nih.gov/25864532 25864532]|[https://pubmed.ncbi.nlm.nih.gov/27344728 27344728]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311] [https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]]|[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]|[https://pubmed.ncbi.nlm.nih.gov/20663960 20663960]|[https://pubmed.ncbi.nlm.nih.gov/18214042 18214042] <br>
-  '''definition''' :  <br>
+  '''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br>
-  '''term_xref''' : GlycoMotif:GGM.000026|GTC:G41145LF <br>
+  '''term_xref''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/91860287 91860287] [https://pubmed.ncbi.nlm.nih.gov/91860287 91860287]]|KEGG:G00181|SugarBind_Ligand:57  <br>
-  '''synonyms''' : 6-sialyl-6-sulfo LN <br>
+  '''synonyms''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br>
-  '''function''' : B-cell interaction with blood vessels and trafficking[PMID: [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
+  '''function''' : promotes metastasis[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : prostate cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000003===
+===GSD000061===
-  '''term (main_entry)''' : 2-Fucosyl-GD1b <br>
+  '''term (main_entry)''' : Disialyl Gb5 <br>
-  '''glycan_dictionary_accession''' : GSD000003 <br>
+  '''glycan_dictionary_accession''' : GSD000061 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67383AR G67383AR] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br>
-  '''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
+  '''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]]]] <br>
-  '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]]] <br>
-  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br>
+  '''definition''' :  <br>
-  '''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR<br>
+  '''term_xref''' : GlycoEpitope:EP0098|GTC:G97932OH|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/91860287 91860287] [https://pubmed.ncbi.nlm.nih.gov/91860287 91860287]]|SugarBind_Ligand:57|KEGG:G00181  <br>
-  '''synonyms''' : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000004===
+===GSD000062===
-  '''term (main_entry)''' : 2-Fucosyl-GM1 <br>
+  '''term (main_entry)''' : Disialyl I <br>
-  '''glycan_dictionary_accession''' : GSD000004 <br>
+  '''glycan_dictionary_accession''' : GSD000062 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56526JU G56526JU] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54937EM G54937EM] <br>
-  '''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
+  '''term_in_sentence''' : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:[https://pubmed.ncbi.nlm.nih.gov/10640401 10640401]] <br>
-  '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10640401 10640401] <br>
-  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br>
+  '''definition''' :  <br>
-  '''term_xref''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU  <br>
+  '''term_xref''' : GlycoEpitope:EP0095|GTC:G54937EM|CID:[https://pubmed.ncbi.nlm.nih.gov/91849523 91849523]  <br>
-  '''synonyms''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br>
+  '''synonyms''' : disialyl-I <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
@@ Line 335: / Line 472: @@
-===GSD000005===
+===GSD000063===
-  '''term (main_entry)''' : 3-Sialyl-LN (type 2) <br>
+  '''term (main_entry)''' : Disialyl Lewis a <br>
-  '''glycan_dictionary_accession''' : GSD000005 <br>
+  '''glycan_dictionary_accession''' : GSD000063 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G10203DW G10203DW] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93400AK G93400AK] <br>
-  '''term_in_sentence''' : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:[https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]] <br>
+  '''term_in_sentence''' : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]|[https://pubmed.ncbi.nlm.nih.gov/15659615 15659615]|[https://pubmed.ncbi.nlm.nih.gov/2414279 2414279]|[https://pubmed.ncbi.nlm.nih.gov/8586620 8586620]|[https://pubmed.ncbi.nlm.nih.gov/2111348 2111348]|[https://pubmed.ncbi.nlm.nih.gov/23747419 23747419] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]|[https://pubmed.ncbi.nlm.nih.gov/12668106 12668106]|[https://pubmed.ncbi.nlm.nih.gov/30716533 30716533]|[https://pubmed.ncbi.nlm.nih.gov/32050430 32050430]|[https://pubmed.ncbi.nlm.nih.gov/22467657 22467657] <br>
-  '''definition''' : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] <br>
+  '''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]] <br>
-  '''term_xref''' : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
+  '''term_xref''' : GTC:G93400AK |GlycoEpitope:EP0040|CID:[https://pubmed.ncbi.nlm.nih.gov/91854138 91854138]|CHEBI:155549 <br>
-  '''synonyms''' : <br>
+  '''synonyms''' : disialyl Lea <br>
-  '''function''' :  <br>
+  '''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br>
-  '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] <br>
+  '''disease_associations''' : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000006===
+===GSD000064===
-  '''term (main_entry)''' : 3'-Sulfo-Lewis a <br>
+  '''term (main_entry)''' : Disialyl T antigen <br>
-  '''glycan_dictionary_accession''' : GSD000006 <br>
+  '''glycan_dictionary_accession''' : GSD000064 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78706CK G78706CK] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G01614ZM G01614ZM] <br>
-  '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br>
+  '''term_in_sentence''' : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/17499486 17499486]|[https://pubmed.ncbi.nlm.nih.gov/17691854 17691854]|[https://pubmed.ncbi.nlm.nih.gov/12944557 12944557]|[https://pubmed.ncbi.nlm.nih.gov/19394320 19394320]|[https://pubmed.ncbi.nlm.nih.gov/7534477 7534477]|[https://pubmed.ncbi.nlm.nih.gov/11604107 11604107]|[https://pubmed.ncbi.nlm.nih.gov/28025252 28025252]|[https://pubmed.ncbi.nlm.nih.gov/9061363 9061363]|[https://pubmed.ncbi.nlm.nih.gov/9878545 9878545]|[https://pubmed.ncbi.nlm.nih.gov/11918697 11918697]|[https://pubmed.ncbi.nlm.nih.gov/24239607 24239607]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/25339106 25339106]|[https://pubmed.ncbi.nlm.nih.gov/21400496 21400496]|[https://pubmed.ncbi.nlm.nih.gov/17998215 17998215]|[https://pubmed.ncbi.nlm.nih.gov/12626387 12626387]|[https://pubmed.ncbi.nlm.nih.gov/11425799 11425799]|[https://pubmed.ncbi.nlm.nih.gov/12219077 12219077]|[https://pubmed.ncbi.nlm.nih.gov/10955596 10955596]|[https://pubmed.ncbi.nlm.nih.gov/9453593 9453593] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/17974963 17974963]|[https://pubmed.ncbi.nlm.nih.gov/33242079 33242079]|[https://pubmed.ncbi.nlm.nih.gov/12645620 12645620]|[https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]|[https://pubmed.ncbi.nlm.nih.gov/26598643 26598643] <br>
-  '''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br>
+  '''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br>
-  '''term_xref''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
+  '''term_xref''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID:[https://pubmed.ncbi.nlm.nih.gov/70698317 70698317]|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027  <br>
-  '''synonyms''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br>
+  '''synonyms''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br>
-  '''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br>
+  '''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
@@ Line 365: / Line 502: @@
-===GSD000007===
+===GSD000065===
-  '''term (main_entry)''' : 3'-Sulfo-Lewis x <br>
+  '''term (main_entry)''' : Disialylated biantennary <br>
-  '''glycan_dictionary_accession''' : GSD000007 <br>
+  '''glycan_dictionary_accession''' : GSD000065 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12295TB G12295TB] <br>
+  '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br>
+  '''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/20695481 20695481]|[https://pubmed.ncbi.nlm.nih.gov/8688428 8688428]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036] [https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]]|[https://pubmed.ncbi.nlm.nih.gov/12770775 12770775]|[https://pubmed.ncbi.nlm.nih.gov/11352731 11352731]|[https://pubmed.ncbi.nlm.nih.gov/9784103 9784103]|[https://pubmed.ncbi.nlm.nih.gov/9022803 9022803] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/17171781 17171781]|[https://pubmed.ncbi.nlm.nih.gov/25022802 25022802]|[https://pubmed.ncbi.nlm.nih.gov/24812685 24812685]|[https://pubmed.ncbi.nlm.nih.gov/24780636 24780636]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382] [https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]]|[https://pubmed.ncbi.nlm.nih.gov/22978794 22978794]|[https://pubmed.ncbi.nlm.nih.gov/22594947 22594947]|[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]|[https://pubmed.ncbi.nlm.nih.gov/20356825 20356825]|[https://pubmed.ncbi.nlm.nih.gov/1634621 1634621]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386] [https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096] [https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]]|[https://pubmed.ncbi.nlm.nih.gov/1472054 1472054]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045] [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|[https://pubmed.ncbi.nlm.nih.gov/19579232 19579232]|[https://pubmed.ncbi.nlm.nih.gov/27943633 27943633] <br>
- '''definition''' : An amino trisaccharide that consists of ''N''-acetyl-β-<small>D</small>-glucosamine having an α-<small>L</small>-fucosyl residue attached at position 3 and a 3-sulfated β-<small>D</small>-galactosyl residue attached at position 4; β-<small>D</small>-Gal''p''3S-(1→4)-[α-<small>L</small>-Fuc''p''-(1→3)]-<small>D</small>-Glc''p''NAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
-  '''term_xref''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029  <br>
+  '''term_xref''' :  <br>
-  '''synonyms''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br>
+  '''synonyms''' : disialylated diantennary <br>
-  '''function''' :  <br>
+  '''function''' : appears in human transferrin[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045] [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382] [https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]]] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000008===
+===GSD000066===
-  '''term (main_entry)''' : 6,6'-bisSulfo-Lewis x <br>
+  '''term (main_entry)''' : Disialylated biantennary complex-type <br>
-  '''glycan_dictionary_accession''' : GSD000008 <br>
+  '''glycan_dictionary_accession''' : GSD000066 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00659GQ G00659GQ] <br>
+  '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] <br>
+  '''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/15175329 15175329]|[https://pubmed.ncbi.nlm.nih.gov/14568956 14568956]|[https://pubmed.ncbi.nlm.nih.gov/12163379 12163379]|[https://pubmed.ncbi.nlm.nih.gov/11919403 11919403]|[https://pubmed.ncbi.nlm.nih.gov/11520459 11520459]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/10200296 10200296]|[https://pubmed.ncbi.nlm.nih.gov/10528213 10528213]|[https://pubmed.ncbi.nlm.nih.gov/9712885 9712885]| [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/9257857 9257857]|[https://pubmed.ncbi.nlm.nih.gov/9164959 9164959]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/8958810 8958810]|[https://pubmed.ncbi.nlm.nih.gov/7560094 7560094]|[https://pubmed.ncbi.nlm.nih.gov/7485559 7485559]|[https://pubmed.ncbi.nlm.nih.gov/7538131 7538131]|[https://pubmed.ncbi.nlm.nih.gov/8161542 8161542]|[https://pubmed.ncbi.nlm.nih.gov/7684905 7684905] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382] [https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386] [https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045] [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096] [https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]]|[https://pubmed.ncbi.nlm.nih.gov/25124522 25124522]|[https://pubmed.ncbi.nlm.nih.gov/19371135 19371135] <br>
- '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br>
+ '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
- '''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ  <br>
+ '''term_xref''' :  <br>
- '''synonyms''' : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x <br>
+ '''synonyms''' :  <br>
- '''function''' : lymphocyte homing[GlycoEpitope:EP0016] <br>
+ '''function''' : appears in human transferrin[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045] [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
- '''disease_associations''' :  <br>
+ '''disease_associations''' : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382] [https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]]] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000009===
+===GSD000067===
-  '''term (main_entry)''' : 6-Sialyl-GalNAc <br>
+  '''term (main_entry)''' : Disialylated fucosylated <br>
-  '''glycan_dictionary_accession''' : GSD000009 <br>
+  '''glycan_dictionary_accession''' : GSD000067 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G08371CD G08371CD] <br>
+  '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]] <br>
+  '''term_in_sentence''' : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]|[https://pubmed.ncbi.nlm.nih.gov/6194157 6194157] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
-  '''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br>
+  '''definition''' : A fucosylated glycan with two sialic acid components. <br>
-  '''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD <br>
+  '''term_xref''' :  <br>
-  '''synonyms''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-===GSD000010===
+===GSD000068===
-  '''term (main_entry)''' : 6-Sulfo LacNac <br>
+  '''term (main_entry)''' : Forssman antigen <br>
-  '''glycan_dictionary_accession''' : GSD000010 <br>
+  '''glycan_dictionary_accession''' : GSD000068 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13157WZ G13157WZ] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br>
-  '''term_in_sentence''' : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]] <br>
+  '''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]|[https://pubmed.ncbi.nlm.nih.gov/31191513 31191513]|[https://pubmed.ncbi.nlm.nih.gov/29977237 29977237]|[https://pubmed.ncbi.nlm.nih.gov/29900053 29900053]|[https://pubmed.ncbi.nlm.nih.gov/30984181 30984181]|[https://pubmed.ncbi.nlm.nih.gov/28732748 28732748]|[https://pubmed.ncbi.nlm.nih.gov/26510404 26510404]|[https://pubmed.ncbi.nlm.nih.gov/28769928 28769928]|[https://pubmed.ncbi.nlm.nih.gov/31154896 31154896]|[https://pubmed.ncbi.nlm.nih.gov/27541644 27541644]|[https://pubmed.ncbi.nlm.nih.gov/25262889 25262889]|[https://pubmed.ncbi.nlm.nih.gov/26155414 26155414]|[https://pubmed.ncbi.nlm.nih.gov/28499587 28499587]|[https://pubmed.ncbi.nlm.nih.gov/27086951 27086951]|[https://pubmed.ncbi.nlm.nih.gov/27315572 27315572]|[https://pubmed.ncbi.nlm.nih.gov/26162403 26162403]|[https://pubmed.ncbi.nlm.nih.gov/26391152 26391152]|[https://pubmed.ncbi.nlm.nih.gov/31730025 31730025]|[https://pubmed.ncbi.nlm.nih.gov/12354382 12354382]|[https://pubmed.ncbi.nlm.nih.gov/27318477 27318477]|[https://pubmed.ncbi.nlm.nih.gov/23879812 23879812]|[https://pubmed.ncbi.nlm.nih.gov/25340085 25340085]|[https://pubmed.ncbi.nlm.nih.gov/24682513 24682513]|[https://pubmed.ncbi.nlm.nih.gov/21377044 21377044]|[https://pubmed.ncbi.nlm.nih.gov/21098395 21098395]|[https://pubmed.ncbi.nlm.nih.gov/18942710 18942710]|[https://pubmed.ncbi.nlm.nih.gov/23559493 23559493]|[https://pubmed.ncbi.nlm.nih.gov/23890755 23890755]|[https://pubmed.ncbi.nlm.nih.gov/22643330 22643330]|[https://pubmed.ncbi.nlm.nih.gov/23460612 23460612]|[https://pubmed.ncbi.nlm.nih.gov/23402811 23402811]|[https://pubmed.ncbi.nlm.nih.gov/22890025 22890025]|[https://pubmed.ncbi.nlm.nih.gov/19589615 19589615]|[https://pubmed.ncbi.nlm.nih.gov/32939325 32939325]|[https://pubmed.ncbi.nlm.nih.gov/20210806 20210806]|[https://pubmed.ncbi.nlm.nih.gov/17616642 17616642]|[https://pubmed.ncbi.nlm.nih.gov/22907335 22907335]|[https://pubmed.ncbi.nlm.nih.gov/16782032 16782032]|[https://pubmed.ncbi.nlm.nih.gov/22188261 22188261]|[https://pubmed.ncbi.nlm.nih.gov/21283706 21283706]|[https://pubmed.ncbi.nlm.nih.gov/29875315 29875315]|[https://pubmed.ncbi.nlm.nih.gov/32413173 32413173]|[https://pubmed.ncbi.nlm.nih.gov/19546436 19546436]|[https://pubmed.ncbi.nlm.nih.gov/19384158 19384158]|[https://pubmed.ncbi.nlm.nih.gov/1429720 1429720]|[https://pubmed.ncbi.nlm.nih.gov/30519676 30519676] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]|[https://pubmed.ncbi.nlm.nih.gov/31933576 31933576]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301] [https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]]|[https://pubmed.ncbi.nlm.nih.gov/7021748 7021748]|[https://pubmed.ncbi.nlm.nih.gov/1802714 1802714]|[https://pubmed.ncbi.nlm.nih.gov/7512587 7512587]|[https://pubmed.ncbi.nlm.nih.gov/7747818 7747818]|[https://pubmed.ncbi.nlm.nih.gov/23325748 23325748]|268649|[https://pubmed.ncbi.nlm.nih.gov/31816281 31816281]|[https://pubmed.ncbi.nlm.nih.gov/22015168 22015168]|[https://pubmed.ncbi.nlm.nih.gov/4147161 4147161]|[https://pubmed.ncbi.nlm.nih.gov/2857159 2857159]|[https://pubmed.ncbi.nlm.nih.gov/6267170 6267170]|[https://pubmed.ncbi.nlm.nih.gov/7293775 7293775]|[https://pubmed.ncbi.nlm.nih.gov/13367419 13367419]|[https://pubmed.ncbi.nlm.nih.gov/20636540 20636540]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]]]|[https://pubmed.ncbi.nlm.nih.gov/23255552 23255552]|[https://pubmed.ncbi.nlm.nih.gov/2675268 2675268]|[https://pubmed.ncbi.nlm.nih.gov/18955372 18955372]|[https://pubmed.ncbi.nlm.nih.gov/7020692 7020692]|[https://pubmed.ncbi.nlm.nih.gov/31784953 31784953]|[https://pubmed.ncbi.nlm.nih.gov/4114942 4114942]|[https://pubmed.ncbi.nlm.nih.gov/31273262 31273262]|[https://pubmed.ncbi.nlm.nih.gov/6257673 6257673]|[https://pubmed.ncbi.nlm.nih.gov/7696847 7696847]|[https://pubmed.ncbi.nlm.nih.gov/1916901 1916901]|[https://pubmed.ncbi.nlm.nih.gov/11169215 11169215]|48262|[https://pubmed.ncbi.nlm.nih.gov/26022515 26022515]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/31404475 31404475]|[https://pubmed.ncbi.nlm.nih.gov/6983878 6983878]|[https://pubmed.ncbi.nlm.nih.gov/8381954 8381954]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785] [https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]]|[https://pubmed.ncbi.nlm.nih.gov/3257757 3257757]|[https://pubmed.ncbi.nlm.nih.gov/6792413 6792413]|[https://pubmed.ncbi.nlm.nih.gov/25039359 25039359] <br>
-  '''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br>
+  '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789] <br>
-  '''term_xref''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005<br>
+  '''term_xref''' : GTC:G80062GG |GlycoEpitope:EP0037|CID[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/91825690 91825690] [https://pubmed.ncbi.nlm.nih.gov/91825690 91825690]]|CHEBI:85789 <br>
-  '''synonyms''' : 6-Sulfo LacNAc <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-===GSD000011===
+===GSD000069===
-[[File:G00672PE.png|thumb|G00672PE]]
+  '''term (main_entry)''' : Forssman glycolipid <br>
-  '''term (main_entry)''' : 6'-Sulfo Sialyl Lewis x <br>
+  '''glycan_dictionary_accession''' : GSD000069 <br>
-  '''glycan_dictionary_accession''' : GSD000011 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00672PE G00672PE] <br>
+  '''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]] <br>
-  '''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]|268649|[https://pubmed.ncbi.nlm.nih.gov/23240079 23240079]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301] [https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]]|[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]|[https://pubmed.ncbi.nlm.nih.gov/1138893 1138893]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]]]|[https://pubmed.ncbi.nlm.nih.gov/10506200 10506200]|[https://pubmed.ncbi.nlm.nih.gov/8855242 8855242]|[https://pubmed.ncbi.nlm.nih.gov/1955453 1955453]|[https://pubmed.ncbi.nlm.nih.gov/1933935 1933935]|[https://pubmed.ncbi.nlm.nih.gov/3355161 3355161]|[https://pubmed.ncbi.nlm.nih.gov/6773959 6773959]|[https://pubmed.ncbi.nlm.nih.gov/14573676 14573676]|[https://pubmed.ncbi.nlm.nih.gov/29898878 29898878]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785] [https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956] [https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]]|[https://pubmed.ncbi.nlm.nih.gov/11214737 11214737]|[https://pubmed.ncbi.nlm.nih.gov/7423202 7423202]|389939|[https://pubmed.ncbi.nlm.nih.gov/3871816 3871816]|[https://pubmed.ncbi.nlm.nih.gov/6187373 6187373]|[https://pubmed.ncbi.nlm.nih.gov/16133832 16133832]|469271|[https://pubmed.ncbi.nlm.nih.gov/3753492 3753492]|[https://pubmed.ncbi.nlm.nih.gov/2695680 2695680]|[https://pubmed.ncbi.nlm.nih.gov/7037611 7037611]|[https://pubmed.ncbi.nlm.nih.gov/25703376 25703376]|[https://pubmed.ncbi.nlm.nih.gov/23798992 23798992]|414913|[https://pubmed.ncbi.nlm.nih.gov/1868069 1868069]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7960243 7960243] [https://pubmed.ncbi.nlm.nih.gov/7960243 7960243]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/32744401 32744401]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19458105 19458105]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036] [https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br>
+  '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br>
-  '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br>
+  '''term_xref''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/91825690 91825690] [https://pubmed.ncbi.nlm.nih.gov/91825690 91825690]]|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br>
-  '''term_xref''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128  <br>
+  '''synonyms''' : Forssman antigen|Globopentosylceramide <br>
-  '''synonyms''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br>
+  '''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]] <br>
-  '''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br>
+  '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] <br>
-  '''disease_associations''' : Influenza[SugarBind_Ligand:128] <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14] <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
+===GSD000070===
+ '''term (main_entry)''' : Fucose-containing tetraantennary <br>
+ '''glycan_dictionary_accession''' : GSD000070 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2550193 2550193]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2550193 2550193] <br>
+ '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/Forssman_antigen <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GSD000012===
+===GSD000071===
-  '''term (main_entry)''' : 9-O-Acetyl GD3 <br>
+  '''term (main_entry)''' : Fucosyl GM1 <br>
-  '''glycan_dictionary_accession''' : GSD000012 <br>
+  '''glycan_dictionary_accession''' : GSD000071 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74121RX G74121RX] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91532KA G91532KA] <br>
-  '''term_in_sentence''' : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]] <br>
+  '''term_in_sentence''' : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]|[https://pubmed.ncbi.nlm.nih.gov/21507905 21507905]|[https://pubmed.ncbi.nlm.nih.gov/17512674 17512674]|[https://pubmed.ncbi.nlm.nih.gov/21930212 21930212]|[https://pubmed.ncbi.nlm.nih.gov/18194438 18194438]|[https://pubmed.ncbi.nlm.nih.gov/20739294 20739294]|[https://pubmed.ncbi.nlm.nih.gov/3216430 3216430]|[https://pubmed.ncbi.nlm.nih.gov/14724245 14724245]|[https://pubmed.ncbi.nlm.nih.gov/31373393 31373393]|[https://pubmed.ncbi.nlm.nih.gov/7558412 7558412]|[https://pubmed.ncbi.nlm.nih.gov/11273644 11273644]|[https://pubmed.ncbi.nlm.nih.gov/17385751 17385751]|[https://pubmed.ncbi.nlm.nih.gov/30694652 30694652]|[https://pubmed.ncbi.nlm.nih.gov/22894715 22894715]|[https://pubmed.ncbi.nlm.nih.gov/12973826 12973826]|[https://pubmed.ncbi.nlm.nih.gov/7859075 7859075]|[https://pubmed.ncbi.nlm.nih.gov/9749956 9749956]|[https://pubmed.ncbi.nlm.nih.gov/9874495 9874495]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/1989525 1989525]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/23478187 23478187]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/8486686 8486686]|[https://pubmed.ncbi.nlm.nih.gov/11465673 11465673]|[https://pubmed.ncbi.nlm.nih.gov/9511990 9511990]|[https://pubmed.ncbi.nlm.nih.gov/29270199 29270199]|[https://pubmed.ncbi.nlm.nih.gov/9268945 9268945]|[https://pubmed.ncbi.nlm.nih.gov/25045067 25045067]|[https://pubmed.ncbi.nlm.nih.gov/21618115 21618115]|[https://pubmed.ncbi.nlm.nih.gov/16434401 16434401]|[https://pubmed.ncbi.nlm.nih.gov/12493756 12493756]|[https://pubmed.ncbi.nlm.nih.gov/2302705 2302705]|[https://pubmed.ncbi.nlm.nih.gov/2198284 2198284]|[https://pubmed.ncbi.nlm.nih.gov/2685488 2685488]|[https://pubmed.ncbi.nlm.nih.gov/9328574 9328574]|[https://pubmed.ncbi.nlm.nih.gov/4055789 4055789]|[https://pubmed.ncbi.nlm.nih.gov/10096568 10096568]|[https://pubmed.ncbi.nlm.nih.gov/1644805 1644805]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6619101 6619101]|[https://pubmed.ncbi.nlm.nih.gov/16880505 16880505]|[https://pubmed.ncbi.nlm.nih.gov/9089399 9089399]|[https://pubmed.ncbi.nlm.nih.gov/29789847 29789847]|[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]|[https://pubmed.ncbi.nlm.nih.gov/19556222 19556222]|[https://pubmed.ncbi.nlm.nih.gov/1660040 1660040]|[https://pubmed.ncbi.nlm.nih.gov/2420639 2420639]|[https://pubmed.ncbi.nlm.nih.gov/9076515 9076515]|[https://pubmed.ncbi.nlm.nih.gov/15926079 15926079]|[https://pubmed.ncbi.nlm.nih.gov/19555091 19555091]|[https://pubmed.ncbi.nlm.nih.gov/2541996 2541996]|[https://pubmed.ncbi.nlm.nih.gov/16211870 16211870]|[https://pubmed.ncbi.nlm.nih.gov/1336587 1336587]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/14967068 14967068]|[https://pubmed.ncbi.nlm.nih.gov/18923900 18923900]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/16941490 16941490]|[https://pubmed.ncbi.nlm.nih.gov/27070150 27070150]|[https://pubmed.ncbi.nlm.nih.gov/8305235 8305235]|[https://pubmed.ncbi.nlm.nih.gov/10602885 10602885]|[https://pubmed.ncbi.nlm.nih.gov/2645049 2645049]|[https://pubmed.ncbi.nlm.nih.gov/7993838 7993838]|[https://pubmed.ncbi.nlm.nih.gov/10537341 10537341]|[https://pubmed.ncbi.nlm.nih.gov/3002616 3002616]|[https://pubmed.ncbi.nlm.nih.gov/8336147 8336147]|[https://pubmed.ncbi.nlm.nih.gov/15447995 15447995]|[https://pubmed.ncbi.nlm.nih.gov/8905401 8905401]|[https://pubmed.ncbi.nlm.nih.gov/11714535 11714535]|[https://pubmed.ncbi.nlm.nih.gov/9260862 9260862]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/3315641 3315641]|[https://pubmed.ncbi.nlm.nih.gov/8076384 8076384]|[https://pubmed.ncbi.nlm.nih.gov/2317201 2317201]|[https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]|[https://pubmed.ncbi.nlm.nih.gov/6403518 6403518] <br>
-  '''definition''' :  <br>
+  '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br>
-  '''term_xref''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
+  '''term_xref''' : GTC:G91532KA |GlycoEpitope:EP0049|CID:[https://pubmed.ncbi.nlm.nih.gov/53356699 53356699]|CHEBI:62686 <br>
-  '''synonyms''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' : pancreas cancer[GlycoEpitope:EP0064] <br>
+  '''disease_associations''' : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000013===
+===GSD000072===
-  '''term (main_entry)''' : 9-O-Acetyl sialic acid <br>
+  '''term (main_entry)''' : Fucosylated asialo-biantennary <br>
-  '''glycan_dictionary_accession''' : GSD000013 <br>
+  '''glycan_dictionary_accession''' : GSD000072 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G47325QT G47325QT] <br>
+  '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]] <br>
+  '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]]] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]|[https://pubmed.ncbi.nlm.nih.gov/27936566 27936566]|[https://pubmed.ncbi.nlm.nih.gov/2509478 2509478]|[https://pubmed.ncbi.nlm.nih.gov/10049046 10049046]|[https://pubmed.ncbi.nlm.nih.gov/1826463 1826463] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932] <br>
-  '''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br>
+  '''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br>
-  '''term_xref''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941  <br>
+  '''term_xref''' :  <br>
-  '''synonyms''' :  <br>
+  '''synonyms''' : fucosylated asialo-diantennary <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]<br>
+  '''essentials_of_glycobiology''' :  <br>
-===GSD000014===
+===GSD000073===
-  '''term (main_entry)''' : Blood group A (Type 2) <br>
+  '''term (main_entry)''' : Fucosylated biantennary <br>
-  '''glycan_dictionary_accession''' : GSD000014 <br>
+  '''glycan_dictionary_accession''' : GSD000073 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74353FF G74353FF] <br>
+  '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]] <br>
+  '''term_in_sentence''' : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]|[https://pubmed.ncbi.nlm.nih.gov/8340255 8340255]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/21901093 21901093]|[https://pubmed.ncbi.nlm.nih.gov/2413709 2413709]|[https://pubmed.ncbi.nlm.nih.gov/8036794 8036794]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/3285099 3285099] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/1933856 1933856] <br>
-  '''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br>
+  '''definition''' : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. <br>
-  '''term_xref''' : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
+  '''term_xref''' :  <br>
-  '''synonyms''' : A Type 2|Blood group A type 2 chain<br>
+  '''synonyms''' : fucosylated bisialo-diantennary <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
+  '''essentials_of_glycobiology''' :  <br>
-===GSD000016===
+===GSD000074===
-  '''term (main_entry)''' : Alpha-gal antigen <br>
+  '''term (main_entry)''' : Fucosylated bisialo-biantennary <br>
-  '''glycan_dictionary_accession''' : GSD000016 <br>
+  '''glycan_dictionary_accession''' : GSD000074 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G24432YB G24432YB] <br>
+  '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]] <br>
+  '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]]] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/29319188 29319188]|[https://pubmed.ncbi.nlm.nih.gov/29481481 29481481]|[https://pubmed.ncbi.nlm.nih.gov/26140655 26140655]|[https://pubmed.ncbi.nlm.nih.gov/30337555 30337555]|[https://pubmed.ncbi.nlm.nih.gov/29235434 29235434]|[https://pubmed.ncbi.nlm.nih.gov/22909134 22909134]|[https://pubmed.ncbi.nlm.nih.gov/28280265 28280265]|[https://pubmed.ncbi.nlm.nih.gov/7532618 7532618]|[https://pubmed.ncbi.nlm.nih.gov/23390540 23390540]|[https://pubmed.ncbi.nlm.nih.gov/22808845 22808845]|[https://pubmed.ncbi.nlm.nih.gov/29898796 29898796]|[https://pubmed.ncbi.nlm.nih.gov/22262104 22262104]| [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/25430953 25430953]|[https://pubmed.ncbi.nlm.nih.gov/22993330 22993330]|[https://pubmed.ncbi.nlm.nih.gov/23578170 23578170]|[https://pubmed.ncbi.nlm.nih.gov/21043478 21043478]|[https://pubmed.ncbi.nlm.nih.gov/28294277 28294277]|[https://pubmed.ncbi.nlm.nih.gov/27696820 27696820]|[https://pubmed.ncbi.nlm.nih.gov/15814276 15814276]|[https://pubmed.ncbi.nlm.nih.gov/17991149 17991149]|[https://pubmed.ncbi.nlm.nih.gov/25577211 25577211]|[https://pubmed.ncbi.nlm.nih.gov/30578545 30578545]|[https://pubmed.ncbi.nlm.nih.gov/19895316 19895316]|[https://pubmed.ncbi.nlm.nih.gov/28068870 28068870]|[https://pubmed.ncbi.nlm.nih.gov/18546155 18546155]|[https://pubmed.ncbi.nlm.nih.gov/32907757 32907757]|[https://pubmed.ncbi.nlm.nih.gov/26485996 26485996]|[https://pubmed.ncbi.nlm.nih.gov/9771839 9771839]|[https://pubmed.ncbi.nlm.nih.gov/12042247 12042247]|[https://pubmed.ncbi.nlm.nih.gov/27567275 27567275]|[https://pubmed.ncbi.nlm.nih.gov/12131678 12131678]|[https://pubmed.ncbi.nlm.nih.gov/23114154 23114154]|[https://pubmed.ncbi.nlm.nih.gov/19184002 19184002]|[https://pubmed.ncbi.nlm.nih.gov/29577591 29577591]|[https://pubmed.ncbi.nlm.nih.gov/29806570 29806570]|[https://pubmed.ncbi.nlm.nih.gov/15638815 15638815]|[https://pubmed.ncbi.nlm.nih.gov/21118731 21118731] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br>
-  '''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br>
+  '''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br>
-  '''term_xref''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330  <br>
+  '''term_xref''' :  <br>
-  '''synonyms''' : a-Gal antigen <br>
+  '''synonyms''' : Fucosylated biantennary <br>
-  '''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br>
+  '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
+  '''essentials_of_glycobiology''' :  <br>
+===GSD000075===
+ '''term (main_entry)''' : Fucosylated LDN <br>
+ '''glycan_dictionary_accession''' : GSD000075 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02240AO G02240AO] <br>
+ '''term_in_sentence''' : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/28151933 28151933]|[https://pubmed.ncbi.nlm.nih.gov/19545571 19545571]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293] <br>
+ '''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br>
+ '''term_xref''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID:[https://pubmed.ncbi.nlm.nih.gov/52921591 52921591]|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
+ '''synonyms''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GSD000017===
+===GSD000076===
-  '''term (main_entry)''' : Alpha-galactosylceramide <br>
+  '''term (main_entry)''' : Fucosylated N-glycans <br>
-  '''glycan_dictionary_accession''' : GSD000017 <br>
+  '''glycan_dictionary_accession''' : GSD000076 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]] <br>
+  '''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]] <br>
- '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]|[https://pubmed.ncbi.nlm.nih.gov/30421497 30421497]|[https://pubmed.ncbi.nlm.nih.gov/31575643 31575643]|[https://pubmed.ncbi.nlm.nih.gov/30745361 30745361]|[https://pubmed.ncbi.nlm.nih.gov/30953000 30953000]|[https://pubmed.ncbi.nlm.nih.gov/30556652 30556652]|[https://pubmed.ncbi.nlm.nih.gov/29617191 29617191]|[https://pubmed.ncbi.nlm.nih.gov/31689579 31689579]|[https://pubmed.ncbi.nlm.nih.gov/28872688 28872688]|[https://pubmed.ncbi.nlm.nih.gov/30195979 30195979]|[https://pubmed.ncbi.nlm.nih.gov/29940370 29940370]|[https://pubmed.ncbi.nlm.nih.gov/27004737 27004737]|[https://pubmed.ncbi.nlm.nih.gov/27198610 27198610]|[https://pubmed.ncbi.nlm.nih.gov/28743554 28743554]|[https://pubmed.ncbi.nlm.nih.gov/31649670 31649670]|[https://pubmed.ncbi.nlm.nih.gov/31484693 31484693]|[https://pubmed.ncbi.nlm.nih.gov/25752588 25752588]|[https://pubmed.ncbi.nlm.nih.gov/21383248 21383248]|[https://pubmed.ncbi.nlm.nih.gov/25527277 25527277]|[https://pubmed.ncbi.nlm.nih.gov/30821985 30821985]|[https://pubmed.ncbi.nlm.nih.gov/28947140 28947140]|[https://pubmed.ncbi.nlm.nih.gov/31244823 31244823]|[https://pubmed.ncbi.nlm.nih.gov/29311431 29311431]|[https://pubmed.ncbi.nlm.nih.gov/30803854 30803854]|[https://pubmed.ncbi.nlm.nih.gov/29576533 29576533]|[https://pubmed.ncbi.nlm.nih.gov/26101952 26101952]|[https://pubmed.ncbi.nlm.nih.gov/31213291 31213291]|[https://pubmed.ncbi.nlm.nih.gov/22412194 22412194]|[https://pubmed.ncbi.nlm.nih.gov/28067024 28067024]|[https://pubmed.ncbi.nlm.nih.gov/31199716 31199716]|[https://pubmed.ncbi.nlm.nih.gov/27354638 27354638]|[https://pubmed.ncbi.nlm.nih.gov/24465013 24465013]|[https://pubmed.ncbi.nlm.nih.gov/25445911 25445911]|[https://pubmed.ncbi.nlm.nih.gov/28120096 28120096]|[https://pubmed.ncbi.nlm.nih.gov/15630427 15630427]|[https://pubmed.ncbi.nlm.nih.gov/27803187 27803187]|[https://pubmed.ncbi.nlm.nih.gov/21392534 21392534]|[https://pubmed.ncbi.nlm.nih.gov/31075434 31075434]|[https://pubmed.ncbi.nlm.nih.gov/22683545 22683545]|[https://pubmed.ncbi.nlm.nih.gov/26191196 26191196]|[https://pubmed.ncbi.nlm.nih.gov/26811064 26811064]|[https://pubmed.ncbi.nlm.nih.gov/23935988 23935988]|[https://pubmed.ncbi.nlm.nih.gov/28623127 28623127]|[https://pubmed.ncbi.nlm.nih.gov/24913977 24913977]|[https://pubmed.ncbi.nlm.nih.gov/25434827 25434827]|[https://pubmed.ncbi.nlm.nih.gov/23420533 23420533]|[https://pubmed.ncbi.nlm.nih.gov/21839133 21839133]|[https://pubmed.ncbi.nlm.nih.gov/25314062 25314062]|[https://pubmed.ncbi.nlm.nih.gov/27325450 27325450]|[https://pubmed.ncbi.nlm.nih.gov/23874157 23874157] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]|[https://pubmed.ncbi.nlm.nih.gov/31141660 31141660]|[https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]|[https://pubmed.ncbi.nlm.nih.gov/29790113 29790113]|[https://pubmed.ncbi.nlm.nih.gov/31931062 31931062] <br>
-  '''definition''' :  <br>
+  '''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br>
   '''term_xref''' :  <br>
-  '''synonyms''' : alpha-GalCer|alpha-GalCers|α-GalCer <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : pancreatic cancer.[PMID: [https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000018===
+===GSD000077===
-  '''term (main_entry)''' : Asialo-biantennary <br>
+  '''term (main_entry)''' : Fucosylated triantennary <br>
-  '''glycan_dictionary_accession''' : GSD000018 <br>
+  '''glycan_dictionary_accession''' : GSD000077 <br>
   '''glytoucan_accession ''' :  <br>
-  '''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:[https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]] <br>
+  '''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]|[https://pubmed.ncbi.nlm.nih.gov/17645671 17645671]|[https://pubmed.ncbi.nlm.nih.gov/20959391 20959391]|[https://pubmed.ncbi.nlm.nih.gov/18615430 18615430]|[https://pubmed.ncbi.nlm.nih.gov/16945378 16945378]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/3084472 3084472]|[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] |[https://pubmed.ncbi.nlm.nih.gov/22911097 22911097]|[https://pubmed.ncbi.nlm.nih.gov/24692304 24692304]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932]|[https://pubmed.ncbi.nlm.nih.gov/7513972 7513972]| [https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/10835250 10835250]|[https://pubmed.ncbi.nlm.nih.gov/9684342 9684342] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920] [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/15051952 15051952]|[https://pubmed.ncbi.nlm.nih.gov/12943224 12943224] <br>
-  '''definition''' :  <br>
+  '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br>
   '''term_xref''' :  <br>
-  '''synonyms''' : asialo diantennary <br>
+  '''synonyms''' :  <br>
+ '''function''' : appears in human alpha-fetoprotein (AFP).[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920] [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]] <br>
+ '''disease_associations''' : neoplastic diseases of the liver[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920] [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] ]|hepatocellular carcinoma[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920] [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]]. <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453068/ Chapter 43]<br>
+===GSD000078===
+ '''term (main_entry)''' : Galabiosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000078 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67988RO G67988RO] <br>
+ '''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:[https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167] [https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]]|[https://pubmed.ncbi.nlm.nih.gov/25582508 25582508]|[https://pubmed.ncbi.nlm.nih.gov/2824515 2824515]|[https://pubmed.ncbi.nlm.nih.gov/4027258 4027258]|[https://pubmed.ncbi.nlm.nih.gov/32854306 32854306]|[https://pubmed.ncbi.nlm.nih.gov/32868283 32868283]|[https://pubmed.ncbi.nlm.nih.gov/31319156 31319156]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250] [https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]]|[https://pubmed.ncbi.nlm.nih.gov/27367163 27367163]|[https://pubmed.ncbi.nlm.nih.gov/2564247 2564247]|[https://pubmed.ncbi.nlm.nih.gov/27727434 27727434]|[https://pubmed.ncbi.nlm.nih.gov/10216186 10216186]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]]]|[https://pubmed.ncbi.nlm.nih.gov/24992926 24992926]|[https://pubmed.ncbi.nlm.nih.gov/23590301 23590301]|[https://pubmed.ncbi.nlm.nih.gov/15702404 15702404]|[https://pubmed.ncbi.nlm.nih.gov/1854798 1854798]|[https://pubmed.ncbi.nlm.nih.gov/14761135 14761135]|[https://pubmed.ncbi.nlm.nih.gov/3600200 3600200]|[https://pubmed.ncbi.nlm.nih.gov/8603914 8603914]|[https://pubmed.ncbi.nlm.nih.gov/8601603 8601603]|[https://pubmed.ncbi.nlm.nih.gov/1965141 1965141]|[https://pubmed.ncbi.nlm.nih.gov/17400502 17400502]|[https://pubmed.ncbi.nlm.nih.gov/3840690 3840690]|[https://pubmed.ncbi.nlm.nih.gov/15959771 15959771]|[https://pubmed.ncbi.nlm.nih.gov/7930586 7930586]|[https://pubmed.ncbi.nlm.nih.gov/7721812 7721812]|[https://pubmed.ncbi.nlm.nih.gov/17095952 17095952]|[https://pubmed.ncbi.nlm.nih.gov/2500499 2500499]|[https://pubmed.ncbi.nlm.nih.gov/3815386 3815386]|[https://pubmed.ncbi.nlm.nih.gov/8842706 8842706]|[https://pubmed.ncbi.nlm.nih.gov/10746023 10746023]|[https://pubmed.ncbi.nlm.nih.gov/3928791 3928791]|[https://pubmed.ncbi.nlm.nih.gov/3782065 3782065]|[https://pubmed.ncbi.nlm.nih.gov/6440894 6440894] <br>
+ '''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br>
+ '''term_xref''' : GlycoEpitope:EP0113|GTC:G67988RO|CID:[https://pubmed.ncbi.nlm.nih.gov/5288350 5288350]|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
+ '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000019===
+===GSD000079===
-[[File:G21856LC.png|thumb|G21856LC]]
+  '''term (main_entry)''' : Galactosylceramide <br>
-  '''term (main_entry)''' : Asialo-GM1 <br>
+  '''glycan_dictionary_accession''' : GSD000079 <br>
-  '''glycan_dictionary_accession''' : GSD000019 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65889KE G65889KE] <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G21856LC G21856LC] <br>
+  '''term_in_sentence''' : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31393621 31393621]] <br>
-  '''term_in_sentence''' : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31393621 31393621]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/9883654 9883654]|[https://pubmed.ncbi.nlm.nih.gov/33006978 33006978]|[https://pubmed.ncbi.nlm.nih.gov/26735924 26735924]|[https://pubmed.ncbi.nlm.nih.gov/22032265 22032265]|[https://pubmed.ncbi.nlm.nih.gov/18035062 18035062]|[https://pubmed.ncbi.nlm.nih.gov/25129050 25129050]|[https://pubmed.ncbi.nlm.nih.gov/2802541 2802541]|[https://pubmed.ncbi.nlm.nih.gov/1761517 1761517]|[https://pubmed.ncbi.nlm.nih.gov/28660574 28660574]|475780|[https://pubmed.ncbi.nlm.nih.gov/2302222 2302222] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]|[https://pubmed.ncbi.nlm.nih.gov/3418980 3418980]|[https://pubmed.ncbi.nlm.nih.gov/26975993 26975993]|[https://pubmed.ncbi.nlm.nih.gov/8613364 8613364]|[https://pubmed.ncbi.nlm.nih.gov/9288228 9288228]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/24922516 24922516]|[https://pubmed.ncbi.nlm.nih.gov/6839313 6839313]|[https://pubmed.ncbi.nlm.nih.gov/1828259 1828259]|[https://pubmed.ncbi.nlm.nih.gov/2581667 2581667]|[https://pubmed.ncbi.nlm.nih.gov/8210226 8210226]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/9671150 9671150]|[https://pubmed.ncbi.nlm.nih.gov/10377092 10377092]|[https://pubmed.ncbi.nlm.nih.gov/6171919 6171919]|[https://pubmed.ncbi.nlm.nih.gov/3093429 3093429]|[https://pubmed.ncbi.nlm.nih.gov/6652964 6652964]|[https://pubmed.ncbi.nlm.nih.gov/3124753 3124753]|[https://pubmed.ncbi.nlm.nih.gov/8905612 8905612]|[https://pubmed.ncbi.nlm.nih.gov/18788941 18788941]|[https://pubmed.ncbi.nlm.nih.gov/1467432 1467432]|[https://pubmed.ncbi.nlm.nih.gov/8225593 8225593]|[https://pubmed.ncbi.nlm.nih.gov/2083955 2083955]|[https://pubmed.ncbi.nlm.nih.gov/6171918 6171918]|[https://pubmed.ncbi.nlm.nih.gov/7806377 7806377]|[https://pubmed.ncbi.nlm.nih.gov/1802483 1802483]|[https://pubmed.ncbi.nlm.nih.gov/7927723 7927723]|[https://pubmed.ncbi.nlm.nih.gov/9209156 9209156]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/2584393 2584393]|[https://pubmed.ncbi.nlm.nih.gov/12137200 12137200]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/2936802 2936802]|[https://pubmed.ncbi.nlm.nih.gov/8610366 8610366]|[https://pubmed.ncbi.nlm.nih.gov/21490162 21490162]|[https://pubmed.ncbi.nlm.nih.gov/1548508 1548508]|[https://pubmed.ncbi.nlm.nih.gov/3486908 3486908]|[https://pubmed.ncbi.nlm.nih.gov/26453755 26453755]|[https://pubmed.ncbi.nlm.nih.gov/7910939 7910939]|[https://pubmed.ncbi.nlm.nih.gov/3756909 3756909]|[https://pubmed.ncbi.nlm.nih.gov/1639356 1639356]|[https://pubmed.ncbi.nlm.nih.gov/3259967 3259967]|[https://pubmed.ncbi.nlm.nih.gov/2443562 2443562]|[https://pubmed.ncbi.nlm.nih.gov/3112077 3112077]|[https://pubmed.ncbi.nlm.nih.gov/2572647 2572647]|[https://pubmed.ncbi.nlm.nih.gov/25137483 25137483]|[https://pubmed.ncbi.nlm.nih.gov/2168971 2168971]|[https://pubmed.ncbi.nlm.nih.gov/6950172 6950172] <br>
   '''definition''' :  <br>
-  '''term_xref''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216  <br>
+  '''term_xref''' : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061<br>
-  '''synonyms''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide <br>
+  '''synonyms''' : GalCer|Galactocerebroside|LC <br>
   '''function''' :  <br>
-  '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] <br>
+  '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000020===
+===GSD000080===
-  '''term (main_entry)''' : B-GD1B <br>
+  '''term (main_entry)''' : Galnac disialyl Lc4 (Hexasaccharide) <br>
-  '''glycan_dictionary_accession''' : GSD000020 <br>
+  '''glycan_dictionary_accession''' : GSD000080 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72557NR G72557NR] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G33532XU G33532XU] <br>
-  '''term_in_sentence''' : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]] <br>
+  '''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]]]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27956354 27956354]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15704108 15704108]|[https://pubmed.ncbi.nlm.nih.gov/11278988 11278988]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]]]|[https://pubmed.ncbi.nlm.nih.gov/7509790 7509790] <br>
+ '''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID:[https://pubmed.ncbi.nlm.nih.gov/91857945 91857945]] <br>
+ '''term_xref''' : GlycoEpitope:EP0097|GTC:G33532XU|CID:[https://pubmed.ncbi.nlm.nih.gov/91857945 91857945]|CHEBI:149360 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000081===
+ '''term (main_entry)''' : Gb5 <br>
+ '''glycan_dictionary_accession''' : GSD000081 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99053DY G99053DY] <br>
+ '''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]|[https://pubmed.ncbi.nlm.nih.gov/31540393 31540393]|[https://pubmed.ncbi.nlm.nih.gov/31140679 31140679]|[https://pubmed.ncbi.nlm.nih.gov/3028540 3028540]|[https://pubmed.ncbi.nlm.nih.gov/3674263 3674263]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142] [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]]|[https://pubmed.ncbi.nlm.nih.gov/30026902 30026902]|[https://pubmed.ncbi.nlm.nih.gov/10721708 10721708]|[https://pubmed.ncbi.nlm.nih.gov/30671362 30671362]|[https://pubmed.ncbi.nlm.nih.gov/26176557 26176557]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255]|[https://pubmed.ncbi.nlm.nih.gov/24044869 24044869]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311] [https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]]|[https://pubmed.ncbi.nlm.nih.gov/27857717 27857717]|[https://pubmed.ncbi.nlm.nih.gov/21491978 21491978]|[https://pubmed.ncbi.nlm.nih.gov/24910250 24910250]|[https://pubmed.ncbi.nlm.nih.gov/29077212 29077212]|[https://pubmed.ncbi.nlm.nih.gov/8014006 8014006]|[https://pubmed.ncbi.nlm.nih.gov/27107335 27107335]|[https://pubmed.ncbi.nlm.nih.gov/32679486 32679486]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956] [https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]]|[https://pubmed.ncbi.nlm.nih.gov/8679447 8679447]|[https://pubmed.ncbi.nlm.nih.gov/28352526 28352526]|[https://pubmed.ncbi.nlm.nih.gov/11341836 11341836]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7960243 7960243] [https://pubmed.ncbi.nlm.nih.gov/7960243 7960243]]|[https://pubmed.ncbi.nlm.nih.gov/16158941 16158941]|[https://pubmed.ncbi.nlm.nih.gov/3297853 3297853]|[https://pubmed.ncbi.nlm.nih.gov/2431136 2431136]|[https://pubmed.ncbi.nlm.nih.gov/21734356 21734356]|[https://pubmed.ncbi.nlm.nih.gov/8625206 8625206]|[https://pubmed.ncbi.nlm.nih.gov/30732055 30732055]|[https://pubmed.ncbi.nlm.nih.gov/12716912 12716912]|[https://pubmed.ncbi.nlm.nih.gov/20128040 20128040]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447]|[https://pubmed.ncbi.nlm.nih.gov/14659673 14659673] <br>
+ '''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br>
+ '''term_xref''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:[https://pubmed.ncbi.nlm.nih.gov/53239691 53239691]|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12<br>
+ '''synonyms''' : Globopentaosylceramide <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
+===GSD000082===
+ '''term (main_entry)''' : GD1 <br>
+ '''glycan_dictionary_accession''' : GSD000082 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G81983KG G81983KG] <br>
+ '''term_in_sentence''' : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/5652802 5652802]|[https://pubmed.ncbi.nlm.nih.gov/25345088 25345088]|[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]|[https://pubmed.ncbi.nlm.nih.gov/29361370 29361370]|[https://pubmed.ncbi.nlm.nih.gov/31234327 31234327]|[https://pubmed.ncbi.nlm.nih.gov/30264864 30264864]|[https://pubmed.ncbi.nlm.nih.gov/25250137 25250137]|[https://pubmed.ncbi.nlm.nih.gov/7528216 7528216]|[https://pubmed.ncbi.nlm.nih.gov/31669751 31669751]|[https://pubmed.ncbi.nlm.nih.gov/20684311 20684311]|[https://pubmed.ncbi.nlm.nih.gov/16306603 16306603]|[https://pubmed.ncbi.nlm.nih.gov/10420586 10420586]|[https://pubmed.ncbi.nlm.nih.gov/7766692 7766692]|[https://pubmed.ncbi.nlm.nih.gov/31614613 31614613]|[https://pubmed.ncbi.nlm.nih.gov/26384672 26384672]|[https://pubmed.ncbi.nlm.nih.gov/31613991 31613991]|[https://pubmed.ncbi.nlm.nih.gov/19210136 19210136]|[https://pubmed.ncbi.nlm.nih.gov/8926633 8926633]|[https://pubmed.ncbi.nlm.nih.gov/29696051 29696051]|[https://pubmed.ncbi.nlm.nih.gov/32300455 32300455]|[https://pubmed.ncbi.nlm.nih.gov/7513313 7513313]|[https://pubmed.ncbi.nlm.nih.gov/26674302 26674302]|[https://pubmed.ncbi.nlm.nih.gov/20336376 20336376]|[https://pubmed.ncbi.nlm.nih.gov/24259734 24259734]|[https://pubmed.ncbi.nlm.nih.gov/31704237 31704237]|[https://pubmed.ncbi.nlm.nih.gov/21067946 21067946]|[https://pubmed.ncbi.nlm.nih.gov/30516933 30516933]|[https://pubmed.ncbi.nlm.nih.gov/27979707 27979707]|[https://pubmed.ncbi.nlm.nih.gov/26345314 26345314]|[https://pubmed.ncbi.nlm.nih.gov/30516941 30516941]|[https://pubmed.ncbi.nlm.nih.gov/31849452 31849452]|[https://pubmed.ncbi.nlm.nih.gov/27789132 27789132]|[https://pubmed.ncbi.nlm.nih.gov/30218706 30218706]|[https://pubmed.ncbi.nlm.nih.gov/29388611 29388611]|[https://pubmed.ncbi.nlm.nih.gov/20177787 20177787] <br>
   '''definition''' :  <br>
-  '''term_xref''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID: 91847819|KEGG:G01803|CHEBI:153361 <br>
+  '''term_xref''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID:[https://pubmed.ncbi.nlm.nih.gov/91859783 91859783]|KEGG:G00126  <br>
-  '''synonyms''' : B-GD1b <br>
+  '''synonyms''' : GD1c <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
@@ Line 562: / Line 772: @@
-===GSD000021===
+===GSD000083===
-  '''term (main_entry)''' : B-GM1 <br>
+  '''term (main_entry)''' : GD1a <br>
-  '''glycan_dictionary_accession''' : GSD000021 <br>
+  '''glycan_dictionary_accession''' : GSD000083 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G11485ID G11485ID] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G46677TE G46677TE] | [https://glygen.org/glycan/G45714BQ G45714BQ]<br>
-  '''term_in_sentence''' : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]] <br>
+  '''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]|[https://pubmed.ncbi.nlm.nih.gov/26860251 26860251]|[https://pubmed.ncbi.nlm.nih.gov/21930390 21930390]|[https://pubmed.ncbi.nlm.nih.gov/32906699 32906699]|[https://pubmed.ncbi.nlm.nih.gov/26054879 26054879]|[https://pubmed.ncbi.nlm.nih.gov/29951721 29951721]|[https://pubmed.ncbi.nlm.nih.gov/11745410 11745410]|[https://pubmed.ncbi.nlm.nih.gov/17653976 17653976]|[https://pubmed.ncbi.nlm.nih.gov/26119566 26119566]|[https://pubmed.ncbi.nlm.nih.gov/21554929 21554929]|[https://pubmed.ncbi.nlm.nih.gov/18435913 18435913]|[https://pubmed.ncbi.nlm.nih.gov/15342262 15342262]|[https://pubmed.ncbi.nlm.nih.gov/26865725 26865725]|[https://pubmed.ncbi.nlm.nih.gov/21151139 21151139]|[https://pubmed.ncbi.nlm.nih.gov/15716397 15716397]|[https://pubmed.ncbi.nlm.nih.gov/21492147 21492147]|[https://pubmed.ncbi.nlm.nih.gov/16942752 16942752]|[https://pubmed.ncbi.nlm.nih.gov/26973195 26973195]|[https://pubmed.ncbi.nlm.nih.gov/24449473 24449473]|[https://pubmed.ncbi.nlm.nih.gov/14999485 14999485]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20589721 20589721]|[https://pubmed.ncbi.nlm.nih.gov/10521808 10521808]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] [https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]]|[https://pubmed.ncbi.nlm.nih.gov/7827024 7827024]|[https://pubmed.ncbi.nlm.nih.gov/16897174 16897174]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/17227759 17227759] <br>
-  '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br>
+  '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br>
-  '''term_xref''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
+ '''term_xref''' : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:[https://pubmed.ncbi.nlm.nih.gov/45266861 45266861]|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111  <br>
+ '''synonyms''' : GD1alpha <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000084===
+[[File:G37184KW.png|thumb|G37184KW]]
+ '''term (main_entry)''' : GD1b <br>
+ '''glycan_dictionary_accession''' : GSD000084 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37184KW G37184KW] <br>
+ '''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332] [https://pubmed.ncbi.nlm.nih.gov/24859332 24859332]]|[https://pubmed.ncbi.nlm.nih.gov/18625966 18625966]|[https://pubmed.ncbi.nlm.nih.gov/7945223 7945223]|[https://pubmed.ncbi.nlm.nih.gov/32518172 32518172]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/31837178 31837178]|[https://pubmed.ncbi.nlm.nih.gov/20594196 20594196]|[https://pubmed.ncbi.nlm.nih.gov/30985655 30985655]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/1742806 1742806]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/7685064 7685064]|[https://pubmed.ncbi.nlm.nih.gov/2709011 2709011]|[https://pubmed.ncbi.nlm.nih.gov/33279873 33279873]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] [https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]]|[https://pubmed.ncbi.nlm.nih.gov/9179156 9179156]|[https://pubmed.ncbi.nlm.nih.gov/17964572 17964572]|[https://pubmed.ncbi.nlm.nih.gov/8821498 8821498]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/26560950 26560950]|[https://pubmed.ncbi.nlm.nih.gov/2611779 2611779]|[https://pubmed.ncbi.nlm.nih.gov/10072058 10072058]|[https://pubmed.ncbi.nlm.nih.gov/20030259 20030259]|[https://pubmed.ncbi.nlm.nih.gov/16415013 16415013]|[https://pubmed.ncbi.nlm.nih.gov/10797556 10797556]|[https://pubmed.ncbi.nlm.nih.gov/11342695 11342695]|[https://pubmed.ncbi.nlm.nih.gov/8619520 8619520]|[https://pubmed.ncbi.nlm.nih.gov/21519903 21519903]|[https://pubmed.ncbi.nlm.nih.gov/16199892 16199892]|[https://pubmed.ncbi.nlm.nih.gov/23777091 23777091]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056] [https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]]|[https://pubmed.ncbi.nlm.nih.gov/10481046 10481046] <br>
+ '''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br>
+ '''term_xref''' : GlycoMotif:GGM.000108|GTC:G37184KW|CID:[https://pubmed.ncbi.nlm.nih.gov/45266846 45266846]|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
+===GSD000085===
+ '''term (main_entry)''' : GD2 <br>
+ '''glycan_dictionary_accession''' : GSD000085 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02657AK G02657AK] <br>
+ '''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: [https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28154831 28154831]|[https://pubmed.ncbi.nlm.nih.gov/32002293 32002293]|[https://pubmed.ncbi.nlm.nih.gov/32733795 32733795]|[https://pubmed.ncbi.nlm.nih.gov/28145567 28145567]|[https://pubmed.ncbi.nlm.nih.gov/31500597 31500597]|[https://pubmed.ncbi.nlm.nih.gov/31903906 31903906]|[https://pubmed.ncbi.nlm.nih.gov/29180536 29180536]|[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]|[https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]|[https://pubmed.ncbi.nlm.nih.gov/30617136 30617136]|[https://pubmed.ncbi.nlm.nih.gov/25604432 25604432]|[https://pubmed.ncbi.nlm.nih.gov/30198960 30198960]|[https://pubmed.ncbi.nlm.nih.gov/31075227 31075227]|[https://pubmed.ncbi.nlm.nih.gov/31721713 31721713]|[https://pubmed.ncbi.nlm.nih.gov/30955398 30955398]|[https://pubmed.ncbi.nlm.nih.gov/32195035 32195035]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202] [https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]]|[https://pubmed.ncbi.nlm.nih.gov/31015228 31015228]|[https://pubmed.ncbi.nlm.nih.gov/31653037 31653037]|[https://pubmed.ncbi.nlm.nih.gov/31016728 31016728]|[https://pubmed.ncbi.nlm.nih.gov/30670592 30670592]|[https://pubmed.ncbi.nlm.nih.gov/30613134 30613134]|[https://pubmed.ncbi.nlm.nih.gov/29221154 29221154]|[https://pubmed.ncbi.nlm.nih.gov/30027525 30027525]|[https://pubmed.ncbi.nlm.nih.gov/29442009 29442009]|[https://pubmed.ncbi.nlm.nih.gov/31762628 31762628]|[https://pubmed.ncbi.nlm.nih.gov/30485077 30485077]|[https://pubmed.ncbi.nlm.nih.gov/25642322 25642322]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609] [https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]]|[https://pubmed.ncbi.nlm.nih.gov/29151270 29151270]|[https://pubmed.ncbi.nlm.nih.gov/24773917 24773917]|[https://pubmed.ncbi.nlm.nih.gov/30612272 30612272]|[https://pubmed.ncbi.nlm.nih.gov/27654028 27654028]|[https://pubmed.ncbi.nlm.nih.gov/26298772 26298772] <br>
+ '''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br>
+  '''term_xref''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID:[https://pubmed.ncbi.nlm.nih.gov/45266844 45266844]|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88  <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' : Cholera[SugarBind_Ligand:181] <br>
+  '''disease_associations''' : breast cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]] <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453073/ Chatper 35]<br>
+===GSD000086===
+ '''term (main_entry)''' : GD3 <br>
+ '''glycan_dictionary_accession''' : GSD000086 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98544DH G98544DH] <br>
+ '''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: [https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30245960 30245960]|[https://pubmed.ncbi.nlm.nih.gov/27591028 27591028]|[https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]|[https://pubmed.ncbi.nlm.nih.gov/29069780 29069780]|[https://pubmed.ncbi.nlm.nih.gov/12470841 12470841]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609] [https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]]|[https://pubmed.ncbi.nlm.nih.gov/28295752 28295752]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202] [https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]]|[https://pubmed.ncbi.nlm.nih.gov/31138648 31138648]|[https://pubmed.ncbi.nlm.nih.gov/27288875 27288875]|[https://pubmed.ncbi.nlm.nih.gov/30446565 30446565]|[https://pubmed.ncbi.nlm.nih.gov/8721669 8721669]|[https://pubmed.ncbi.nlm.nih.gov/3903474 3903474]|[https://pubmed.ncbi.nlm.nih.gov/16081368 16081368]|[https://pubmed.ncbi.nlm.nih.gov/32743804 32743804]|[https://pubmed.ncbi.nlm.nih.gov/24372645 24372645]|[https://pubmed.ncbi.nlm.nih.gov/26792897 26792897]|[https://pubmed.ncbi.nlm.nih.gov/20890432 20890432]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/20581115 20581115]|[https://pubmed.ncbi.nlm.nih.gov/11174200 11174200]|[https://pubmed.ncbi.nlm.nih.gov/16040804 16040804]|[https://pubmed.ncbi.nlm.nih.gov/23783008 23783008]|[https://pubmed.ncbi.nlm.nih.gov/17368571 17368571]|[https://pubmed.ncbi.nlm.nih.gov/11023989 11023989]|[https://pubmed.ncbi.nlm.nih.gov/12901230 12901230]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/7061953 7061953]|[https://pubmed.ncbi.nlm.nih.gov/2231782 2231782]|[https://pubmed.ncbi.nlm.nih.gov/19423750 19423750]|[https://pubmed.ncbi.nlm.nih.gov/22632091 22632091]|[https://pubmed.ncbi.nlm.nih.gov/18202973 18202973]|[https://pubmed.ncbi.nlm.nih.gov/6392333 6392333]|[https://pubmed.ncbi.nlm.nih.gov/15896784 15896784]|[https://pubmed.ncbi.nlm.nih.gov/8261439 8261439]|[https://pubmed.ncbi.nlm.nih.gov/20052288 20052288]|[https://pubmed.ncbi.nlm.nih.gov/12847141 12847141]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/12118012 12118012]|[https://pubmed.ncbi.nlm.nih.gov/19912988 19912988]|[https://pubmed.ncbi.nlm.nih.gov/22795094 22795094]|[https://pubmed.ncbi.nlm.nih.gov/18655184 18655184]|[https://pubmed.ncbi.nlm.nih.gov/17043769 17043769]|[https://pubmed.ncbi.nlm.nih.gov/21395555 21395555]|[https://pubmed.ncbi.nlm.nih.gov/2472199 2472199]|[https://pubmed.ncbi.nlm.nih.gov/19776077 19776077] <br>
+ '''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br>
+ '''term_xref''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID:[https://pubmed.ncbi.nlm.nih.gov/45266862 45266862]|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GSD000022===
+===GSD000087===
-  '''term (main_entry)''' : Biantennary <br>
+  '''term (main_entry)''' : Globoside <br>
-  '''glycan_dictionary_accession''' : GSD000022 <br>
+  '''glycan_dictionary_accession''' : GSD000087 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br>
-  '''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]] <br>
+  '''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:[https://pubmed.ncbi.nlm.nih.gov/10993897 10993897]] <br>
-  '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]| [https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/29409839 29409839]| [https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/18083109 18083109]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/16715395 16715395]| [https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/24211369 24211369]|[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31907993 31907993]| [https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/20861009 20861009]| [https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/11442281 11442281]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/15680603 15680603]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]| [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]]| [https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]| [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/9346821 9346821]|[https://pubmed.ncbi.nlm.nih.gov/19341309 19341309]|[https://pubmed.ncbi.nlm.nih.gov/18529007 18529007]| [https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/10463590 10463590]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/15316280 15316280]|[https://pubmed.ncbi.nlm.nih.gov/8068637 8068637]|[https://pubmed.ncbi.nlm.nih.gov/3881425 3881425]| [https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/8576139 8576139]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/1576211 1576211]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583]|[https://pubmed.ncbi.nlm.nih.gov/30421263 30421263]|[https://pubmed.ncbi.nlm.nih.gov/8069634 8069634]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]| [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]| [https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/29806066 29806066]|[https://pubmed.ncbi.nlm.nih.gov/29443078 29443078] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10993897 10993897] <br>
-  '''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
+  '''definition''' :  <br>
-  '''term_xref''' :  <br>
+  '''term_xref''' : GlycoMotif:GGM.000070|GTC:G00061MO  <br>
-  '''synonyms''' : diantennary <br>
+  '''synonyms''' : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
+===GSD000088===
+ '''term (main_entry)''' : Globotetraosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000088 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br>
+ '''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]|[https://pubmed.ncbi.nlm.nih.gov/25787850 25787850]|[https://pubmed.ncbi.nlm.nih.gov/23471986 23471986]|[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]|[https://pubmed.ncbi.nlm.nih.gov/32455599 32455599]|[https://pubmed.ncbi.nlm.nih.gov/2663859 2663859]|[https://pubmed.ncbi.nlm.nih.gov/32796033 32796033]|[https://pubmed.ncbi.nlm.nih.gov/3517161 3517161]|[https://pubmed.ncbi.nlm.nih.gov/20082214 20082214]|[https://pubmed.ncbi.nlm.nih.gov/30853699 30853699]|[https://pubmed.ncbi.nlm.nih.gov/15279935 15279935]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/20732996 20732996]|[https://pubmed.ncbi.nlm.nih.gov/30224239 30224239]|[https://pubmed.ncbi.nlm.nih.gov/31142708 31142708]|[https://pubmed.ncbi.nlm.nih.gov/30338271 30338271]|[https://pubmed.ncbi.nlm.nih.gov/25033755 25033755]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389] [https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]]|[https://pubmed.ncbi.nlm.nih.gov/7104376 7104376]|[https://pubmed.ncbi.nlm.nih.gov/29866658 29866658]|[https://pubmed.ncbi.nlm.nih.gov/24983355 24983355]|[https://pubmed.ncbi.nlm.nih.gov/6794884 6794884]|[https://pubmed.ncbi.nlm.nih.gov/31361021 31361021]|[https://pubmed.ncbi.nlm.nih.gov/21740983 21740983]|[https://pubmed.ncbi.nlm.nih.gov/33168837 33168837]|[https://pubmed.ncbi.nlm.nih.gov/31752441 31752441]|[https://pubmed.ncbi.nlm.nih.gov/28123520 28123520]|[https://pubmed.ncbi.nlm.nih.gov/29068380 29068380]|[https://pubmed.ncbi.nlm.nih.gov/24841197 24841197]|[https://pubmed.ncbi.nlm.nih.gov/27932383 27932383]|[https://pubmed.ncbi.nlm.nih.gov/28535204 28535204]|[https://pubmed.ncbi.nlm.nih.gov/31691795 31691795]|[https://pubmed.ncbi.nlm.nih.gov/27916888 27916888]|[https://pubmed.ncbi.nlm.nih.gov/27558838 27558838]|[https://pubmed.ncbi.nlm.nih.gov/10227680 10227680]|[https://pubmed.ncbi.nlm.nih.gov/26464281 26464281]|[https://pubmed.ncbi.nlm.nih.gov/22348006 22348006]|[https://pubmed.ncbi.nlm.nih.gov/22279060 22279060]|[https://pubmed.ncbi.nlm.nih.gov/25156739 25156739]|[https://pubmed.ncbi.nlm.nih.gov/32314902 32314902]|[https://pubmed.ncbi.nlm.nih.gov/22718629 22718629]|[https://pubmed.ncbi.nlm.nih.gov/23701631 23701631]|[https://pubmed.ncbi.nlm.nih.gov/23906628 23906628]|[https://pubmed.ncbi.nlm.nih.gov/8613382 8613382]|[https://pubmed.ncbi.nlm.nih.gov/23555772 23555772]|[https://pubmed.ncbi.nlm.nih.gov/20059899 20059899]|[https://pubmed.ncbi.nlm.nih.gov/7868240 7868240] <br>
+ '''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br>
+ '''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:[https://pubmed.ncbi.nlm.nih.gov/5288889 5288889]|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032<br>
+ '''synonyms''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GSD000023===
+===GSD000089===
-  '''term (main_entry)''' : Biantennary complex <br>
+[[File:G00061MO.png|thumb|G00061MO]]
-  '''glycan_dictionary_accession''' : GSD000023 <br>
+  '''term (main_entry)''' : Globotriaosylceramide <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glycan_dictionary_accession''' : GSD000089 <br>
-  '''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/3731182 3731182]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]| [https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/28597152 28597152]|[https://pubmed.ncbi.nlm.nih.gov/25045879 25045879]|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]| [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/7691595 7691595]|[https://pubmed.ncbi.nlm.nih.gov/26780731 26780731]|[https://pubmed.ncbi.nlm.nih.gov/16285669 16285669]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/3924097 3924097]|[https://pubmed.ncbi.nlm.nih.gov/30448401 30448401]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/29408873 29408873] <br>
+  '''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]] <br>
-  '''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]|[https://pubmed.ncbi.nlm.nih.gov/28674962 28674962]|[https://pubmed.ncbi.nlm.nih.gov/30875019 30875019]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389] [https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]]|[https://pubmed.ncbi.nlm.nih.gov/31778662 31778662]|[https://pubmed.ncbi.nlm.nih.gov/31101366 31101366]|[https://pubmed.ncbi.nlm.nih.gov/24335674 24335674]|[https://pubmed.ncbi.nlm.nih.gov/31241709 31241709]|[https://pubmed.ncbi.nlm.nih.gov/24158513 24158513]|[https://pubmed.ncbi.nlm.nih.gov/28947349 28947349]|[https://pubmed.ncbi.nlm.nih.gov/31566927 31566927]|[https://pubmed.ncbi.nlm.nih.gov/28672034 28672034]|[https://pubmed.ncbi.nlm.nih.gov/31939530 31939530]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250] [https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]]|[https://pubmed.ncbi.nlm.nih.gov/27851774 27851774]|[https://pubmed.ncbi.nlm.nih.gov/26426881 26426881]|[https://pubmed.ncbi.nlm.nih.gov/25031264 25031264]|[https://pubmed.ncbi.nlm.nih.gov/29982630 29982630]|[https://pubmed.ncbi.nlm.nih.gov/24496231 24496231]|[https://pubmed.ncbi.nlm.nih.gov/29983334 29983334]|[https://pubmed.ncbi.nlm.nih.gov/28756410 28756410]|[https://pubmed.ncbi.nlm.nih.gov/27190352 27190352]|[https://pubmed.ncbi.nlm.nih.gov/29274327 29274327]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167] [https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]]|[https://pubmed.ncbi.nlm.nih.gov/28402705 28402705]|[https://pubmed.ncbi.nlm.nih.gov/23680766 23680766]|[https://pubmed.ncbi.nlm.nih.gov/28625968 28625968]|[https://pubmed.ncbi.nlm.nih.gov/26960552 26960552]|[https://pubmed.ncbi.nlm.nih.gov/26797827 26797827]|[https://pubmed.ncbi.nlm.nih.gov/22742555 22742555]|[https://pubmed.ncbi.nlm.nih.gov/27756537 27756537]|[https://pubmed.ncbi.nlm.nih.gov/31630715 31630715]|[https://pubmed.ncbi.nlm.nih.gov/3827883 3827883]|[https://pubmed.ncbi.nlm.nih.gov/28384397 28384397]|[https://pubmed.ncbi.nlm.nih.gov/29523338 29523338]|[https://pubmed.ncbi.nlm.nih.gov/31010832 31010832]|[https://pubmed.ncbi.nlm.nih.gov/27195818 27195818]|[https://pubmed.ncbi.nlm.nih.gov/26661087 26661087]|[https://pubmed.ncbi.nlm.nih.gov/23093409 23093409]|[https://pubmed.ncbi.nlm.nih.gov/30879639 30879639]|[https://pubmed.ncbi.nlm.nih.gov/27081853 27081853]|[https://pubmed.ncbi.nlm.nih.gov/17409683 17409683]|[https://pubmed.ncbi.nlm.nih.gov/29921669 29921669]|[https://pubmed.ncbi.nlm.nih.gov/25575293 25575293]|[https://pubmed.ncbi.nlm.nih.gov/26291612 26291612]|[https://pubmed.ncbi.nlm.nih.gov/23146289 23146289]|[https://pubmed.ncbi.nlm.nih.gov/25857295 25857295]|[https://pubmed.ncbi.nlm.nih.gov/26070511 26070511] <br>
-  '''term_xref''' : CHEBI:156251 <br>
+  '''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br>
-  '''synonyms''' : diantennary complex type <br>
+  '''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:[https://pubmed.ncbi.nlm.nih.gov/5279515 5279515]|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27  <br>
+  '''synonyms''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br>
   '''function''' :  <br>
-  '''disease_associations''' :  <br>
+  '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>
-===GSD000024===
+===GSD000090===
-  '''term (main_entry)''' : Bisecting GlcNac <br>
+  '''term (main_entry)''' : Glucosylceramide <br>
-  '''glycan_dictionary_accession''' : GSD000024 <br>
+  '''glycan_dictionary_accession''' : GSD000090 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G71142DF G71142DF] <br>
-  '''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]] <br>
+  '''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/29909448 29909448]|[https://pubmed.ncbi.nlm.nih.gov/29274553 29274553]|[https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]|[https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]|[https://pubmed.ncbi.nlm.nih.gov/31375533 31375533]|[https://pubmed.ncbi.nlm.nih.gov/26467158 26467158]|[https://pubmed.ncbi.nlm.nih.gov/27429195 27429195]|[https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]|[https://pubmed.ncbi.nlm.nih.gov/26109616 26109616]|[https://pubmed.ncbi.nlm.nih.gov/30542567 30542567]|[https://pubmed.ncbi.nlm.nih.gov/30144245 30144245]|[https://pubmed.ncbi.nlm.nih.gov/25727145 25727145]|[https://pubmed.ncbi.nlm.nih.gov/29593568 29593568]|[https://pubmed.ncbi.nlm.nih.gov/32612952 32612952]|[https://pubmed.ncbi.nlm.nih.gov/9006930 9006930]|[https://pubmed.ncbi.nlm.nih.gov/19508951 19508951]|[https://pubmed.ncbi.nlm.nih.gov/16000695 16000695]|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/19053837 19053837]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/30405631 30405631]|[https://pubmed.ncbi.nlm.nih.gov/19940114 19940114]|[https://pubmed.ncbi.nlm.nih.gov/32719549 32719549]|[https://pubmed.ncbi.nlm.nih.gov/9560299 9560299]|[https://pubmed.ncbi.nlm.nih.gov/29655002 29655002]|[https://pubmed.ncbi.nlm.nih.gov/10589784 10589784]|[https://pubmed.ncbi.nlm.nih.gov/29959030 29959030]|[https://pubmed.ncbi.nlm.nih.gov/20661133 20661133]|[https://pubmed.ncbi.nlm.nih.gov/9061364 9061364]|[https://pubmed.ncbi.nlm.nih.gov/31065629 31065629]|[https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]|[https://pubmed.ncbi.nlm.nih.gov/29549127 29549127]|[https://pubmed.ncbi.nlm.nih.gov/30305426 30305426]|[https://pubmed.ncbi.nlm.nih.gov/29632412 29632412]|[https://pubmed.ncbi.nlm.nih.gov/24108122 24108122]|[https://pubmed.ncbi.nlm.nih.gov/24282611 24282611]|[https://pubmed.ncbi.nlm.nih.gov/27821068 27821068]|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/10816579 10816579]|[https://pubmed.ncbi.nlm.nih.gov/25032906 25032906]|[https://pubmed.ncbi.nlm.nih.gov/30025558 30025558]|[https://pubmed.ncbi.nlm.nih.gov/9661906 9661906]|[https://pubmed.ncbi.nlm.nih.gov/8542600 8542600]|[https://pubmed.ncbi.nlm.nih.gov/31585439 31585439]|[https://pubmed.ncbi.nlm.nih.gov/29699572 29699572]|[https://pubmed.ncbi.nlm.nih.gov/27443163 27443163]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/23808883 23808883]|[https://pubmed.ncbi.nlm.nih.gov/18812317 18812317]|[https://pubmed.ncbi.nlm.nih.gov/19776078 19776078] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]|[https://pubmed.ncbi.nlm.nih.gov/29290548 29290548]|[https://pubmed.ncbi.nlm.nih.gov/29627573 29627573]|[https://pubmed.ncbi.nlm.nih.gov/20919653 20919653]|[https://pubmed.ncbi.nlm.nih.gov/28427052 28427052]|[https://pubmed.ncbi.nlm.nih.gov/30550553 30550553]|[https://pubmed.ncbi.nlm.nih.gov/24415933 24415933]|[https://pubmed.ncbi.nlm.nih.gov/31914593 31914593]|[https://pubmed.ncbi.nlm.nih.gov/31051284 31051284]|[https://pubmed.ncbi.nlm.nih.gov/23073611 23073611]|[https://pubmed.ncbi.nlm.nih.gov/30146946 30146946]|[https://pubmed.ncbi.nlm.nih.gov/31619618 31619618]|[https://pubmed.ncbi.nlm.nih.gov/26840726 26840726]|[https://pubmed.ncbi.nlm.nih.gov/29750412 29750412]|[https://pubmed.ncbi.nlm.nih.gov/8065509 8065509]|[https://pubmed.ncbi.nlm.nih.gov/27412675 27412675]|[https://pubmed.ncbi.nlm.nih.gov/27840079 27840079]|[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]|[https://pubmed.ncbi.nlm.nih.gov/31353719 31353719]|[https://pubmed.ncbi.nlm.nih.gov/25661072 25661072]|[https://pubmed.ncbi.nlm.nih.gov/28686011 28686011]|[https://pubmed.ncbi.nlm.nih.gov/25803043 25803043]|[https://pubmed.ncbi.nlm.nih.gov/28865794 28865794]|[https://pubmed.ncbi.nlm.nih.gov/28154347 28154347]|[https://pubmed.ncbi.nlm.nih.gov/31466334 31466334]|[https://pubmed.ncbi.nlm.nih.gov/30242129 30242129]|[https://pubmed.ncbi.nlm.nih.gov/12531551 12531551]|[https://pubmed.ncbi.nlm.nih.gov/30639288 30639288]|[https://pubmed.ncbi.nlm.nih.gov/30864417 30864417]|[https://pubmed.ncbi.nlm.nih.gov/27711049 27711049]|[https://pubmed.ncbi.nlm.nih.gov/22764777 22764777]|[https://pubmed.ncbi.nlm.nih.gov/27905603 27905603]|[https://pubmed.ncbi.nlm.nih.gov/29077010 29077010]|[https://pubmed.ncbi.nlm.nih.gov/28744000 28744000]|[https://pubmed.ncbi.nlm.nih.gov/23555901 23555901]|[https://pubmed.ncbi.nlm.nih.gov/24115322 24115322]|[https://pubmed.ncbi.nlm.nih.gov/12803919 12803919]|[https://pubmed.ncbi.nlm.nih.gov/29204666 29204666]|[https://pubmed.ncbi.nlm.nih.gov/23628459 23628459]|[https://pubmed.ncbi.nlm.nih.gov/28851512 28851512]|[https://pubmed.ncbi.nlm.nih.gov/26136173 26136173]|[https://pubmed.ncbi.nlm.nih.gov/23563543 23563543]|[https://pubmed.ncbi.nlm.nih.gov/30110701 30110701]|[https://pubmed.ncbi.nlm.nih.gov/26572681 26572681]|[https://pubmed.ncbi.nlm.nih.gov/2193825 2193825]|[https://pubmed.ncbi.nlm.nih.gov/29926415 29926415]|[https://pubmed.ncbi.nlm.nih.gov/31727994 31727994]|[https://pubmed.ncbi.nlm.nih.gov/27479571 27479571] <br>
-  '''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]] <br>
+ '''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br>
-  '''term_xref''' : SID:163312364|KEGG:G13066<br>
+ '''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF<br>
+  '''synonyms''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br>
+ '''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br>
+  '''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453065/ Chapter 31]<br>
+===GSD000091===
+[[File:G48558GR.png|thumb|G48558GR]]
+ '''term (main_entry)''' : GM1 <br>
+ '''glycan_dictionary_accession''' : GSD000091 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br>
+ '''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18524657 18524657]|[https://pubmed.ncbi.nlm.nih.gov/31761138 31761138]|[https://pubmed.ncbi.nlm.nih.gov/36180805 36180805]|[https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]|[https://pubmed.ncbi.nlm.nih.gov/33859490 33859490]'''|'''[https://pubmed.ncbi.nlm.nih.gov/31937438 31937438]|[https://pubmed.ncbi.nlm.nih.gov/25762012 25762012]|[https://pubmed.ncbi.nlm.nih.gov/25931034 25931034]|[https://pubmed.ncbi.nlm.nih.gov/31776384 31776384]|[https://pubmed.ncbi.nlm.nih.gov/32013258 32013258]|[https://pubmed.ncbi.nlm.nih.gov/30776097 30776097]|[https://pubmed.ncbi.nlm.nih.gov/31048748 31048748]|[https://pubmed.ncbi.nlm.nih.gov/31447771 31447771]|[https://pubmed.ncbi.nlm.nih.gov/30292198 30292198]|[https://pubmed.ncbi.nlm.nih.gov/28796418 28796418]|[https://pubmed.ncbi.nlm.nih.gov/27806275 27806275]|[https://pubmed.ncbi.nlm.nih.gov/21076871 21076871]|[https://pubmed.ncbi.nlm.nih.gov/27552916 27552916]|[https://pubmed.ncbi.nlm.nih.gov/17986147 17986147]|[https://pubmed.ncbi.nlm.nih.gov/26960162 26960162]|[https://pubmed.ncbi.nlm.nih.gov/27815022 27815022]|[https://pubmed.ncbi.nlm.nih.gov/25851126 25851126]|[https://pubmed.ncbi.nlm.nih.gov/32916822 32916822]|[https://pubmed.ncbi.nlm.nih.gov/11462671 11462671]|[https://pubmed.ncbi.nlm.nih.gov/28236574 28236574]|[https://pubmed.ncbi.nlm.nih.gov/15911874 15911874]|[https://pubmed.ncbi.nlm.nih.gov/28577204 28577204]|[https://pubmed.ncbi.nlm.nih.gov/28497346 28497346]|[https://pubmed.ncbi.nlm.nih.gov/1794005 1794005]|[https://pubmed.ncbi.nlm.nih.gov/31934908 31934908]|[https://pubmed.ncbi.nlm.nih.gov/30267299 30267299]|[https://pubmed.ncbi.nlm.nih.gov/16902585 16902585]|[https://pubmed.ncbi.nlm.nih.gov/29439846 29439846]|[https://pubmed.ncbi.nlm.nih.gov/32325905 32325905]|[https://pubmed.ncbi.nlm.nih.gov/29747823 29747823]|[https://pubmed.ncbi.nlm.nih.gov/27576485 27576485]|[https://pubmed.ncbi.nlm.nih.gov/26338710 26338710]|[https://pubmed.ncbi.nlm.nih.gov/27858734 27858734]|[https://pubmed.ncbi.nlm.nih.gov/24501414 24501414]|[https://pubmed.ncbi.nlm.nih.gov/26818965 26818965]|[https://pubmed.ncbi.nlm.nih.gov/26629687 26629687]|[https://pubmed.ncbi.nlm.nih.gov/26958633 26958633]|[https://pubmed.ncbi.nlm.nih.gov/1854596 1854596]|[https://pubmed.ncbi.nlm.nih.gov/32134593 32134593]|[https://pubmed.ncbi.nlm.nih.gov/32198666 32198666]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/6619101 6619101] [https://pubmed.ncbi.nlm.nih.gov/6619101 6619101]] <br>
+ '''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br>
+ '''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
+ '''synonyms''' :  GM1 ganglioside|GM1-ganglioside<br>
+ '''function''' :  The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16267866/ 16267866]]<br>
+ '''disease_associations''' : GM1 gangliosidosis (GM1) [PMID: [https://pubmed.ncbi.nlm.nih.gov/33859490/ 33859490]]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/GM1 <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]| [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14] <br>
+===GSD000092===
+ '''term (main_entry)''' : GM2 <br>
+ '''glycan_dictionary_accession''' : GSD000092 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
+ '''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29618308 29618308]|[https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]|[https://pubmed.ncbi.nlm.nih.gov/32867370 32867370]|[https://pubmed.ncbi.nlm.nih.gov/30030044 30030044]|[https://pubmed.ncbi.nlm.nih.gov/27499644 27499644]|[https://pubmed.ncbi.nlm.nih.gov/31097363 31097363]|[https://pubmed.ncbi.nlm.nih.gov/29100724 29100724]|[https://pubmed.ncbi.nlm.nih.gov/27402091 27402091]|[https://pubmed.ncbi.nlm.nih.gov/31852956 31852956]|[https://pubmed.ncbi.nlm.nih.gov/30389374 30389374]|[https://pubmed.ncbi.nlm.nih.gov/30988135 30988135]|[https://pubmed.ncbi.nlm.nih.gov/8786814 8786814]|[https://pubmed.ncbi.nlm.nih.gov/14533808 14533808]|[https://pubmed.ncbi.nlm.nih.gov/23370522 23370522]|[https://pubmed.ncbi.nlm.nih.gov/28192816 28192816]|[https://pubmed.ncbi.nlm.nih.gov/32692591 32692591]|[https://pubmed.ncbi.nlm.nih.gov/29106755 29106755]|[https://pubmed.ncbi.nlm.nih.gov/28833537 28833537]|[https://pubmed.ncbi.nlm.nih.gov/11339652 11339652]|[https://pubmed.ncbi.nlm.nih.gov/9728335 9728335]|[https://pubmed.ncbi.nlm.nih.gov/27270764 27270764]|[https://pubmed.ncbi.nlm.nih.gov/9714704 9714704]|[https://pubmed.ncbi.nlm.nih.gov/26175473 26175473]|[https://pubmed.ncbi.nlm.nih.gov/27018595 27018595]|[https://pubmed.ncbi.nlm.nih.gov/28615102 28615102]|[https://pubmed.ncbi.nlm.nih.gov/28974375 28974375]|[https://pubmed.ncbi.nlm.nih.gov/32951593 32951593]|[https://pubmed.ncbi.nlm.nih.gov/11462672 11462672]|[https://pubmed.ncbi.nlm.nih.gov/28955902 28955902]|[https://pubmed.ncbi.nlm.nih.gov/17192692 17192692]|[https://pubmed.ncbi.nlm.nih.gov/26538065 26538065]|[https://pubmed.ncbi.nlm.nih.gov/25421609 25421609]|[https://pubmed.ncbi.nlm.nih.gov/9572057 9572057]|[https://pubmed.ncbi.nlm.nih.gov/11596983 11596983]|[https://pubmed.ncbi.nlm.nih.gov/15264019 15264019]|[https://pubmed.ncbi.nlm.nih.gov/23236285 23236285]|[https://pubmed.ncbi.nlm.nih.gov/11596984 11596984]|[https://pubmed.ncbi.nlm.nih.gov/31261761 31261761]|[https://pubmed.ncbi.nlm.nih.gov/30113798 30113798]|[https://pubmed.ncbi.nlm.nih.gov/24391178 24391178]|[https://pubmed.ncbi.nlm.nih.gov/24309906 24309906]|[https://pubmed.ncbi.nlm.nih.gov/22224667 22224667]|[https://pubmed.ncbi.nlm.nih.gov/7980537 7980537]|[https://pubmed.ncbi.nlm.nih.gov/18272501 18272501]|[https://pubmed.ncbi.nlm.nih.gov/9006924 9006924]| <br>
+ '''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
+ '''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID:[https://pubmed.ncbi.nlm.nih.gov/45266845 45266845]|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/GM1_gangliosidoses <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
+===GSD000093===
+ '''term (main_entry)''' : GM3 <br>
+ '''glycan_dictionary_accession''' : GSD000093 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91237TK G91237TK] <br>
+ '''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: [https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29376491 29376491]|[https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]|[https://pubmed.ncbi.nlm.nih.gov/25613425 25613425]|[https://pubmed.ncbi.nlm.nih.gov/30318083 30318083]|[https://pubmed.ncbi.nlm.nih.gov/31526872 31526872]|[https://pubmed.ncbi.nlm.nih.gov/31004109 31004109]|[https://pubmed.ncbi.nlm.nih.gov/28019668 28019668]|[https://pubmed.ncbi.nlm.nih.gov/26434718 26434718]|[https://pubmed.ncbi.nlm.nih.gov/27313500 27313500]|[https://pubmed.ncbi.nlm.nih.gov/27539856 27539856]|[https://pubmed.ncbi.nlm.nih.gov/30111401 30111401]|[https://pubmed.ncbi.nlm.nih.gov/28544772 28544772]|[https://pubmed.ncbi.nlm.nih.gov/29407985 29407985]|[https://pubmed.ncbi.nlm.nih.gov/19364317 19364317]|[https://pubmed.ncbi.nlm.nih.gov/30190430 30190430]|[https://pubmed.ncbi.nlm.nih.gov/31297734 31297734]|[https://pubmed.ncbi.nlm.nih.gov/30091781 30091781]|[https://pubmed.ncbi.nlm.nih.gov/26043887 26043887]|[https://pubmed.ncbi.nlm.nih.gov/32183071 32183071]|[https://pubmed.ncbi.nlm.nih.gov/30665141 30665141]|[https://pubmed.ncbi.nlm.nih.gov/27873002 27873002]|[https://pubmed.ncbi.nlm.nih.gov/25801320 25801320]|[https://pubmed.ncbi.nlm.nih.gov/30209782 30209782]|[https://pubmed.ncbi.nlm.nih.gov/32378734 32378734]|[https://pubmed.ncbi.nlm.nih.gov/23050851 23050851]|[https://pubmed.ncbi.nlm.nih.gov/22768242 22768242]|[https://pubmed.ncbi.nlm.nih.gov/14993837 14993837]|[https://pubmed.ncbi.nlm.nih.gov/24934090 24934090]|[https://pubmed.ncbi.nlm.nih.gov/17638075 17638075]|[https://pubmed.ncbi.nlm.nih.gov/21518140 21518140]|[https://pubmed.ncbi.nlm.nih.gov/26102277 26102277]|[https://pubmed.ncbi.nlm.nih.gov/19759399 19759399]|[https://pubmed.ncbi.nlm.nih.gov/24502144 24502144]|[https://pubmed.ncbi.nlm.nih.gov/25303960 25303960]|[https://pubmed.ncbi.nlm.nih.gov/23564406 23564406]|[https://pubmed.ncbi.nlm.nih.gov/16636105 16636105]|[https://pubmed.ncbi.nlm.nih.gov/16491123 16491123]|[https://pubmed.ncbi.nlm.nih.gov/11259118 11259118]|[https://pubmed.ncbi.nlm.nih.gov/15102521 15102521]|[https://pubmed.ncbi.nlm.nih.gov/12724312 12724312]|[https://pubmed.ncbi.nlm.nih.gov/24985965 24985965]|[https://pubmed.ncbi.nlm.nih.gov/8496625 8496625]|[https://pubmed.ncbi.nlm.nih.gov/25403557 25403557]|[https://pubmed.ncbi.nlm.nih.gov/15690123 15690123]|[https://pubmed.ncbi.nlm.nih.gov/15939439 15939439]|[https://pubmed.ncbi.nlm.nih.gov/25893133 25893133]|[https://pubmed.ncbi.nlm.nih.gov/23591593 23591593]|[https://pubmed.ncbi.nlm.nih.gov/20634908 20634908]|[https://pubmed.ncbi.nlm.nih.gov/2004380 2004380]|739008| <br>
+ '''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br>
+ '''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID:[https://pubmed.ncbi.nlm.nih.gov/5288424 5288424]|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
   '''synonyms''' :  <br>
-  '''function''' : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]]Inhibits growth factor signaling and retards mammary tumor progression[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]]Integrin-mediated cell adhesion [PMID: [https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: [https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]] <br>
+  '''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br>
- '''disease_associations''' : mammary tumor.[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]] <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>
+===GSD000094===
+[[File:G30207PZ.png|thumb|G30207PZ]]
+ '''term (main_entry)''' : GM4 <br>
+ '''glycan_dictionary_accession''' : GSD000094 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br>
+ '''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]|[https://pubmed.ncbi.nlm.nih.gov/2332419 2332419]|[https://pubmed.ncbi.nlm.nih.gov/12091485 12091485]|[https://pubmed.ncbi.nlm.nih.gov/19542236 19542236]|[https://pubmed.ncbi.nlm.nih.gov/8407875 8407875]|[https://pubmed.ncbi.nlm.nih.gov/23320941 23320941]|[https://pubmed.ncbi.nlm.nih.gov/28808804 28808804]|[https://pubmed.ncbi.nlm.nih.gov/3621237 3621237]|[https://pubmed.ncbi.nlm.nih.gov/23203271 23203271]|[https://pubmed.ncbi.nlm.nih.gov/7057115 7057115]|[https://pubmed.ncbi.nlm.nih.gov/26362868 26362868]|[https://pubmed.ncbi.nlm.nih.gov/6170387 6170387]|[https://pubmed.ncbi.nlm.nih.gov/18034482 18034482]|[https://pubmed.ncbi.nlm.nih.gov/7076644 7076644]|[https://pubmed.ncbi.nlm.nih.gov/2391348 2391348]|[https://pubmed.ncbi.nlm.nih.gov/25464080 25464080]|[https://pubmed.ncbi.nlm.nih.gov/3701369 3701369]|[https://pubmed.ncbi.nlm.nih.gov/11217952 11217952]|[https://pubmed.ncbi.nlm.nih.gov/6201236 6201236]|[https://pubmed.ncbi.nlm.nih.gov/30744426 30744426]|[https://pubmed.ncbi.nlm.nih.gov/9388026 9388026]|[https://pubmed.ncbi.nlm.nih.gov/27177620 27177620]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056] [https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]]|[https://pubmed.ncbi.nlm.nih.gov/15979459 15979459]|[https://pubmed.ncbi.nlm.nih.gov/7586078 7586078]|[https://pubmed.ncbi.nlm.nih.gov/6779816 6779816]|[https://pubmed.ncbi.nlm.nih.gov/29402905 29402905]|[https://pubmed.ncbi.nlm.nih.gov/7335153 7335153]|[https://pubmed.ncbi.nlm.nih.gov/3306476 3306476]|[https://pubmed.ncbi.nlm.nih.gov/17499534 17499534]|[https://pubmed.ncbi.nlm.nih.gov/7074082 7074082]|[https://pubmed.ncbi.nlm.nih.gov/9668345 9668345]|[https://pubmed.ncbi.nlm.nih.gov/3701884 3701884]|[https://pubmed.ncbi.nlm.nih.gov/26862430 26862430]|[https://pubmed.ncbi.nlm.nih.gov/6831238 6831238]|[https://pubmed.ncbi.nlm.nih.gov/27311552 27311552]|[https://pubmed.ncbi.nlm.nih.gov/26831445 26831445]|[https://pubmed.ncbi.nlm.nih.gov/24417799 24417799]|[https://pubmed.ncbi.nlm.nih.gov/7097284 7097284]|[https://pubmed.ncbi.nlm.nih.gov/4169231 4169231]|[https://pubmed.ncbi.nlm.nih.gov/16854400 16854400]|[https://pubmed.ncbi.nlm.nih.gov/26483798 26483798] <br>
+ '''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
+ [CHEBI:63155] <br>
+ '''term_xref''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:[https://pubmed.ncbi.nlm.nih.gov/5289366 5289366]|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
+ '''synonyms''' :  Sialylated GalCer<br>
+ '''function''' :  <br>
+ '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]|[https://www.ncbi.nlm.nih.gov/books/NBK453095/ Chapter 44]|[https://www.ncbi.nlm.nih.gov/books/NBK453018/ Appendix 45A] <br>
-===GSD000025===
-  '''term (main_entry)''' : Bisialo-biantennary <br>
+===GSD000095===
-  '''glycan_dictionary_accession''' : GSD000025 <br>
+  '''term (main_entry)''' : GP1c <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glycan_dictionary_accession''' : GSD000095 <br>
-  '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br>
+  '''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]] <br>
-  '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858] [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]]|[https://pubmed.ncbi.nlm.nih.gov/4091974 4091974]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425] [https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656] [https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350] [https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875] [https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]]|[https://pubmed.ncbi.nlm.nih.gov/11432974 11432974]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845] [https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]]|[https://pubmed.ncbi.nlm.nih.gov/1879553 1879553]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]]|[https://pubmed.ncbi.nlm.nih.gov/8969459 8969459]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286] [https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]]|[https://pubmed.ncbi.nlm.nih.gov/1304332 1304332]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001] [https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]] <br>
-  '''term_xref''' :  <br>
+  '''definition''' :  <br>
-  '''synonyms''' : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary <br>
+  '''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV<br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]|[https://www.ncbi.nlm.nih.gov/books/NBK453076/ Chapter 27]|[https://www.ncbi.nlm.nih.gov/books/NBK453073/ Chapter 35]|[https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45] |[https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]|[https://www.ncbi.nlm.nih.gov/books/NBK453088/ Chapter 49] <br>
-===GSD000026===
+===GSD000096===
-  '''term (main_entry)''' : Bisialo-biantennary complex-type <br>
+  '''term (main_entry)''' : GQ1b <br>
-  '''glycan_dictionary_accession''' : GSD000026 <br>
+  '''glycan_dictionary_accession''' : GSD000096 <br>
-  '''glytoucan_accession ''' :  <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br>
-  '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]] <br>
+  '''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30798387 30798387]|[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]|[https://pubmed.ncbi.nlm.nih.gov/26704905 26704905]|[https://pubmed.ncbi.nlm.nih.gov/23677659 23677659]|[https://pubmed.ncbi.nlm.nih.gov/26984947 26984947]|[https://pubmed.ncbi.nlm.nih.gov/24184316 24184316]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237] [https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]]|[https://pubmed.ncbi.nlm.nih.gov/9819299 9819299]|[https://pubmed.ncbi.nlm.nih.gov/18514410 18514410]|[https://pubmed.ncbi.nlm.nih.gov/22189683 22189683]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332] [https://pubmed.ncbi.nlm.nih.gov/24859332 24859332]] <br>
-  '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  <br>
+  '''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br>
-  '''term_xref''' :  <br>
+  '''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:[https://pubmed.ncbi.nlm.nih.gov/45266843 45266843]|KEGG:G00117|CHEBI:59212  <br>
-  '''synonyms''' : Fully sialylated biantennary N-glycan <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453089/ Chapter 25]<br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GSD000027===
+===GSD000097===
-  '''term (main_entry)''' : Blood group A (Type 2) - Lewis y <br>
+  '''term (main_entry)''' : GQ1ba <br>
-  '''glycan_dictionary_accession''' : GSD000027 <br>
+  '''glycan_dictionary_accession''' : GSD000097 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54826OZ G54826OZ] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54733XO G54733XO] <br>
-  '''term_in_sentence''' : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:[https://pubmed.ncbi.nlm.nih.gov/2417620 2417620]] <br>
+  '''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2417620 2417620] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]|[https://pubmed.ncbi.nlm.nih.gov/23717411 23717411]|[https://pubmed.ncbi.nlm.nih.gov/17870542 17870542]|[https://pubmed.ncbi.nlm.nih.gov/10702226 10702226]|[https://pubmed.ncbi.nlm.nih.gov/21137678 21137678]|[https://pubmed.ncbi.nlm.nih.gov/26748510 26748510]|[https://pubmed.ncbi.nlm.nih.gov/8662799 8662799]|[https://pubmed.ncbi.nlm.nih.gov/21274438 21274438]|[https://pubmed.ncbi.nlm.nih.gov/24649890 24649890]|[https://pubmed.ncbi.nlm.nih.gov/16580208 16580208]|[https://pubmed.ncbi.nlm.nih.gov/28124591 28124591]|[https://pubmed.ncbi.nlm.nih.gov/20095613 20095613]|[https://pubmed.ncbi.nlm.nih.gov/17507233 17507233]|[https://pubmed.ncbi.nlm.nih.gov/23565921 23565921]|[https://pubmed.ncbi.nlm.nih.gov/14505645 14505645]|[https://pubmed.ncbi.nlm.nih.gov/20930939 20930939]|[https://pubmed.ncbi.nlm.nih.gov/9201997 9201997] <br>
-  '''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br>
+  '''definition''' :  <br>
-  '''term_xref''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039  <br>
+  '''term_xref''' : GlycoMotif:GGM.000116|GTC:G54733XO  <br>
-  '''synonyms''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br>
+  '''synonyms''' : GQ1balpha <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
@@ Line 667: / Line 1,002: @@
-===GSD000028===
+===GSD000098===
-  '''term (main_entry)''' : Blood group A (Type 4) <br>
+  '''term (main_entry)''' : GQ1c <br>
-  '''glycan_dictionary_accession''' : GSD000028 <br>
+  '''glycan_dictionary_accession''' : GSD000098 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37830TX G37830TX] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br>
-  '''term_in_sentence''' : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166]] <br>
+  '''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/7521740 7521740]|[https://pubmed.ncbi.nlm.nih.gov/2458640 2458640]|[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858] [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/1729139 1729139]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656] [https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]]|[https://pubmed.ncbi.nlm.nih.gov/20368669 20368669]|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/1814411 1814411]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875] [https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]]|[https://pubmed.ncbi.nlm.nih.gov/6085330 6085330]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/17883393 17883393]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845] [https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425] [https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]]|[https://pubmed.ncbi.nlm.nih.gov/8219015 8219015]|[https://pubmed.ncbi.nlm.nih.gov/8804704 8804704]|[https://pubmed.ncbi.nlm.nih.gov/1384262 1384262]|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/2299192 2299192]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]]|[https://pubmed.ncbi.nlm.nih.gov/10350354 10350354]|[https://pubmed.ncbi.nlm.nih.gov/1304337 1304337]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001] [https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]]|[https://pubmed.ncbi.nlm.nih.gov/11959025 11959025]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350] [https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]]|[https://pubmed.ncbi.nlm.nih.gov/3942818 3942818]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286] [https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]]|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620] <br>
-  '''definition''' :  <br>
+  '''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:[https://pubmed.ncbi.nlm.nih.gov/91860352 91860352]] <br>
-  '''term_xref''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48  <br>
+  '''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID:[https://pubmed.ncbi.nlm.nih.gov/91860352 91860352]|CHEBI:145645|KEGG:G00121 <br>
   '''synonyms''' :  <br>
   '''function''' :  <br>
-  '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] <br>
+  '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
-  '''essentials_of_glycobiology''' :  <br>
+  '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453044/ Chapter 46]<br>
-===GSD000029===
+===GSD000099===
-  '''term (main_entry)''' : Blood group A trisaccharide <br>
+  '''term (main_entry)''' : GT1a <br>
-  '''glycan_dictionary_accession''' : GSD000029 <br>
+  '''glycan_dictionary_accession''' : GSD000099 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00066MO G00066MO] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br>
-  '''term_in_sentence''' : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]] <br>
+  '''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19582848 19582848]|[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]|[https://pubmed.ncbi.nlm.nih.gov/8774717 8774717]|[https://pubmed.ncbi.nlm.nih.gov/2749874 2749874]|[https://pubmed.ncbi.nlm.nih.gov/28771597 28771597]|[https://pubmed.ncbi.nlm.nih.gov/30619340 30619340]|[https://pubmed.ncbi.nlm.nih.gov/2122121 2122121]|[https://pubmed.ncbi.nlm.nih.gov/11886841 11886841]|[https://pubmed.ncbi.nlm.nih.gov/2991755 2991755]|[https://pubmed.ncbi.nlm.nih.gov/12588002 12588002]|[https://pubmed.ncbi.nlm.nih.gov/3149698 3149698]|[https://pubmed.ncbi.nlm.nih.gov/7048329 7048329]|[https://pubmed.ncbi.nlm.nih.gov/7015594 7015594]|[https://pubmed.ncbi.nlm.nih.gov/10359132 10359132]|[https://pubmed.ncbi.nlm.nih.gov/8724140 8724140]|[https://pubmed.ncbi.nlm.nih.gov/1418679 1418679]|[https://pubmed.ncbi.nlm.nih.gov/1446307 1446307] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]|[https://pubmed.ncbi.nlm.nih.gov/9585812 9585812]|[https://pubmed.ncbi.nlm.nih.gov/29747820 29747820]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237] [https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]]|[https://pubmed.ncbi.nlm.nih.gov/11993188 11993188]|[https://pubmed.ncbi.nlm.nih.gov/31683059 31683059]|[https://pubmed.ncbi.nlm.nih.gov/19631994 19631994]|[https://pubmed.ncbi.nlm.nih.gov/9742882 9742882]|[https://pubmed.ncbi.nlm.nih.gov/29709941 29709941]|[https://pubmed.ncbi.nlm.nih.gov/8971119 8971119]|[https://pubmed.ncbi.nlm.nih.gov/8706663 8706663]|893404|[https://pubmed.ncbi.nlm.nih.gov/31829433 31829433]|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/30600291 30600291]|[https://pubmed.ncbi.nlm.nih.gov/29319803 29319803]|[https://pubmed.ncbi.nlm.nih.gov/26176883 26176883]|[https://pubmed.ncbi.nlm.nih.gov/29063860 29063860]|[https://pubmed.ncbi.nlm.nih.gov/6766128 6766128]|[https://pubmed.ncbi.nlm.nih.gov/31602715 31602715]|[https://pubmed.ncbi.nlm.nih.gov/29808463 29808463]|[https://pubmed.ncbi.nlm.nih.gov/30711390 30711390]|[https://pubmed.ncbi.nlm.nih.gov/29847988 29847988]|[https://pubmed.ncbi.nlm.nih.gov/30116054 30116054]|[https://pubmed.ncbi.nlm.nih.gov/28187751 28187751] <br>
-  '''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br>
+  '''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br>
-  '''term_xref''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012  <br>
+  '''term_xref''' : CID:[https://pubmed.ncbi.nlm.nih.gov/45266863 45266863]|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215  <br>
-  '''synonyms''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br>
+  '''synonyms''' :  <br>
   '''function''' :  <br>
   '''disease_associations''' :  <br>
@@ Line 697: / Line 1,032: @@
-===GSD000030===
+===GSD000100===
-  '''term (main_entry)''' : Blood group A (Type 1) <br>
+  '''term (main_entry)''' : GT1a alpha <br>
-  '''glycan_dictionary_accession''' : GSD000030 <br>
+  '''glycan_dictionary_accession''' : GSD000100 <br>
-  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G66163TI G66163TI] <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02149VR G02149VR] <br>
-  '''term_in_sentence''' : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199]] <br>
+  '''term_in_sentence''' : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]] <br>
-  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10942408 10942408]|[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199] <br>
+  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7710562 7710562]|[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]|[https://pubmed.ncbi.nlm.nih.gov/10972137 10972137]|[https://pubmed.ncbi.nlm.nih.gov/9468624 9468624]|[https://pubmed.ncbi.nlm.nih.gov/9143254 9143254]|[https://pubmed.ncbi.nlm.nih.gov/8221098 8221098]|[https://pubmed.ncbi.nlm.nih.gov/9679279 9679279]|[https://pubmed.ncbi.nlm.nih.gov/11368158 11368158]|[https://pubmed.ncbi.nlm.nih.gov/11878808 11878808] <br>
-  '''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br>
+  '''definition''' :  <br>
-  '''term_xref''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
+  '''term_xref''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:[https://pubmed.ncbi.nlm.nih.gov/91851751 91851751]|CHEBI:156678|KEGG:G00128  <br>
-  '''synonyms''' : Blood group A(1)|blood group A antigen type 1 <br>
+  '''synonyms''' : GT1aa <br>
-  '''function''' :  <br>
+  '''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br>
   '''disease_associations''' :  <br>
   '''wikipedia''' :  <br>
   '''essentials_of_glycobiology''' :  <br>

Testhyperlink123: Difference between revisions

Revision as of 18:29, 10 April 2023

GSD000031

GSD000032

GSD000033

GSD000034

GSD000035

GSD000036

GSD000037

GSD000038

GSD000039

GSD000040

GSD000041

GSD000043

GSD000044

GSD000045

GSD000046

GSD000047

GSD000048

GSD000049

GSD000050

GSD000051

GSD000052

GSD000053

GSD000054

GSD000055

GSD000056

GSD000057

GSD000058

GSD000059

GSD000060

GSD000061

GSD000062

GSD000063

GSD000064

GSD000065

GSD000066

GSD000067

GSD000068

GSD000069

GSD000070

GSD000071

GSD000072

GSD000073

GSD000074

GSD000075

GSD000076

GSD000077

GSD000078

GSD000079

GSD000080

GSD000081

GSD000082

GSD000083

GSD000084

GSD000085

GSD000086

GSD000087

GSD000088

GSD000089

GSD000090

GSD000091

GSD000092

GSD000093

GSD000094

GSD000095

GSD000096

GSD000097

GSD000098

GSD000099

GSD000100

Navigation menu